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ABSTRACT
Background
Abnormal glucose regulation (AGR) including impaired glucose tolerance (IGT) and diabetes mellitus 
type 2 (T2DM) are common in patients with stable and unstable coronary artery disease (CAD) and 
impair their prognosis. Available glucose lowering interventions have not fully succeeded in improving 
the detrimental prognosis and accurate screening methods and new treatment strategies are needed.
The aims of this thesis were to
1. decrease the restenosis rate after percutaneous coronary intervention (PCI) in patients with T2DM
2. validate the oral glucose tolerance test (OGTT) for the detection of glucose disturbances in   
 patients with acute coronary syndromes (ACS)
3. evaluate the accuracy of a technique for continuous glucose monitoring in patients in the   
 coronary care unit (CCU)
4. improve beta-cell function in patients with ACS and newly detected AGR
Restenosis in patients with T2DM (Study I)
The restenosis rate six months after PCI was investigated in 93 patients with T2DM randomised to 
either intensive glucose control by means of insulin (I group; n=44) or to continue ongoing glucose-
lowering treatment (C group; n=49). At the end of the follow-up period restenosis rate was available in 
82 patients. The glucose control did not differ between the two groups (change in HbA1c -0.2 vs.-0.1%; 
p=0.3 and in fasting blood glucose +0.2 vs. -0.3 mmol/L; p=0.3 in the I and C groups). The restenosis 
rate was 41% in the I and 44% in the C group (p=0.8). Independent predictors for restenosis were pre-
vious myocardial infarction (OR 8.0, 95% CI 2.5–25.7; p<0.001) and fasting blood glucose at baseline 
(OR 1.4, 95% CI 1.1–1.9; p=0.015).
Screening for glucose abnormalities in ACS (Studies II and III)
The value of an OGTT for screening of unknown AGR in patients with ACS was explored. Infarct size 
did not influence the result but patients with transmural myocardial infarctions (MI) (n=70) had higher 
glucose levels at admission and fasting during the next two days (7.0, 5.7, 5.4 mmol/L) compared to 
those with subendocardial MI (n=102; 6.0, 5.3, 5.0 mmol/L; p<0.001, p=0.01, p=0.004; Study II). 
More patients were classified as T2DM according to OGTT (n=27) compared to fasting plasma glucose 
(n=10) and HbA1c (n=2; Study III).
Continuous glucose monitoring in the coronary care unit (Study IV)
The accuracy of an intravenously inserted microdialysis catheter intended for continuous glucose moni-
toring was validated in 14 patients in a CCU setting. Although predominantly delivering correct values, 
the stability over time was insufficient.  Thus the microdialysis technique requires further improve-
ments to be useful in this setting.
Beta-cell function in ACS (Study V)
The effect of a DPP-IV inhibitor on beta-cell function, expressed as insulinogenic index (IGI) and acute 
insulin response to glucose (AIRg), in patients with ACS and newly discovered AGR was investigated 
by randomising 34 such patients to sitagliptin (S) and 37 to placebo (P). After 12 weeks of treatment the 
IGI improved in the sitagliptin group (S: 69.9 to 85.0 vs. P: 66.4 to 58.1 pmol/mmol; p=0.019) as did 
the AIRg (S:1394 to 1909 vs. P:1106 to 1043 pmol • l-1 • min-1; p<0.0001). Insulin resistance remained 
unaffected.
Conclusion
It is difficult to achieve glucose normalisation in patients with T2DM and CAD by means of available 
drugs. Early detection of AGR in patients with ACS is essential and an OGTT is a useful tool. 
New technology in the form of equipment for continuous glucose monitoring and novel treatment stra-
tegies e.g. DPP-IV inhibitors deserves further attention in attempts to improve the management and 
thereby prognosis in this vulnerable patient category.
         Glucose-lowering and risk assessment in CHD
7
SAMMANFATTNING
Bakgrund
Störd glukosomsättning (AGR) som nedsatt glukostolerans (IGT) och diabetes mellitus typ 2 (T2DM) 
är vanligt förekommande hos patienter med stabil och instabil koronarsjukdom (CAD) och försämrar 
deras prognos. Tillgänglig glukossänkande behandling har inte förbättrat den dåliga prognosen och 
det finns ett behov av tillförlitliga screeningmetoder och nya behandlingsstrategier.
Syftet med denna avhandling är att 
1. minska frekvensen av restenoser efter perkutan koronar intervention (PCI) vid T2DM.  
2. validera oralt glukostoleranstest (OGTT) som metod att upptäcka glukosstörningar hos   
 patienter med akut koronart syndrom (ACS).
3. utvärdera mätnoggrannheten hos en teknik avsedd för kontinuerlig glukosövervakning av   
 patienter på hjärtintensivvårdavdelningar. 
4. förbättra beta-cellfunktionen hos patienter med ACS och nyupptäckt AGR.
Restenos hos patienter med T2DM (Studie I)
Restenos-frekvensen sex månader efter PCI undersöktes hos 93 patienter med T2DM varav 44 ran-
domiserats till insulinbaserad intensivbehandling (I-gruppen) och 49 till att fortsätta den pågående 
glukossänkande behandlingen (C-gruppen). Efter uppföljningstiden kunde förekomsten av restenos 
utvärderas hos 82 patienter. Det förelåg ingen skillnad i glukoskontroll mellan grupperna (förändring 
av HbA1c I: -0.2 jämfört med C: -0.1%; p=0.3 och i fastande blodglukos +0.2 jämfört med -0.3 
mmol/L; p=0.3 i I- och C-grupperna). Frekvensen av restenoser var 41% i I-gruppen och 44% i C-
gruppen (p=0.8). Oberoende prediktorer för restenos var tidigare hjärtinfarkt (OR 8.0, 95% CI 2.5–
25.7; p<0.001) samt fastande blodglukos vid randomiseringen (OR 1.4, 95% CI 1.1–1.9; p=0.015).
Screening av glukosstörningar hos patienter med ACS (Studie II och III)
Värdet av ett OGTT för screening av okänd AGR hos patienter med ACS undersöktes. Resultaten 
påverkades inte av infarktstorlek men patienter med en transmural hjärtinfarkt (n=70) hade högre 
glukosnivåer vid ankomsten och de två följande dagarna (7.0, 5.7, 5.4 mmol/L) jämfört med patien-
ter med en sub-endokardiell hjärtinfarkt (n=102; 6.0, 5.3, 5.0 mmol/L; p<0.001, p=0.01, p=0.004; 
Studie II). Fler patienter med T2DM klassificerades enligt OGTT (n=27) jämfört med fasteglukos 
(n=10) och HbA1c (n=2; Studie III).
Kontinuerlig glukosmonitorering på hjärtintensiven (Studie IV)
Mätnoggrannheten hos en intravenöst applicerad mikrodialyskateter avsedd för kontinuerlig glukos-
monitorering utvärderades hos 14 hjärtintensivvårdade patienter. Även om flertalet mätpunkter var 
korrekta var stabiliteten över tid otillräcklig. Således behöver mikrodialystekniken förbättras för att 
vara användbar i detta sammanhang.
Beta-cell funktion hos patienter med ACS (Studie V)
En DPP-IV-hämmares effekt på beta-cellfunktionen, uttryckt som insulinogenic index (IGI) och akut 
insulinsvar på glukos (AIRg), undersöktes hos patienter med ACS och nyupptäckt AGR genom att 
randomisera 34 patienter till sitagliptin (S) och 37 till placebo (P). Efter 12 veckors behandling 
hade patienterna i sitagliptin gruppen förbättrat IGI (S: 69.9 till 85.0 jämfört med P: 66.4 till 58.1 
pmol/mmol; p=0.019) och AIRg (S:1394 till 1909 jämfört med P:1106 till 1043 pmol • l-1 • min-1; 
p<0.0001). Insulinresistensen var oförändrad.
Sammanfattning
Det är svårt att åstadkomma en normalisering av glukosnivåerna hos patienter med T2DM och CAD 
med tillgängliga glukossänkande behandlingsalternativ. Tidig upptäckt av AGR hos patienter med 
ACS är angeläget och OGTT är för detta en användbar metod. Ny teknologi i form av kontinuerlig 
glukosmonitorering och nya behandlingsmetoder såsom DPP-IV-hämmare bör tas i beaktande i för-
söken att förbättra behandling och därmed prognos hos denna sårbara kategori av patienter.
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LIST OF ABBREVIATIONS
ACS acute coronary syndrome
ADA American Diabetes Association
AGE advanced glycation end products
AIRg acute insulin response to glucose
AMI acute myocardial infarction
BMS bare metal stent
CABG coronary bypass surgery
CAD coronary artery disease
CCU coronary care unit
CGMS continuous glucose monitoring system
CHD coronary heart disease
CVD cardiovascular disease
DCCT Diabetes Control and Complications Trial
DES drug eluting stent 
DM diabetes mellitus
DPP-IV dipeptidyl peptidase-4
FBG fasting blood glucose
FPG fasting plasma glucose
FSIGT frequently sampled intravenous glucose tolerance test
GIP glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide
GLP-1 glucagon-like peptide-1
HbA1c glycated haemoglobin A1c
HOMA-IR homeostatic model assessment insulin resistance 
IFCC International Federation of Clinical Chemistry
IFG impaired fasting glucose
IGI insulinogenic index
IGT  impaired glucose tolerance
MAPK mitogen activated protein kinase
MI myocardial infarction 
NGT normal glucose tolerance
NSTEMI non ST-elevation myocardial infarction
OGTT oral glucose tolerance test
PCI percutaneous coronary intervention
PI3K phosphatidylinostol-3 kinase
STEMI ST-elevation myocardial infarction
T1DM diabetes mellitus type 1
T2DM diabetes mellitus type 2
VSMC vascular smooth muscle cells
WHO World Health Organisation
2hPG plasma glucose two hours after start of OGTT
Camilla Hage
10
INTRODUCTION
Diabetes mellitus
History 
Diabetes mellitus (DM) is an ancient disease. Its symptoms were described as early as 3,500 
years ago in a compendium of medical diseases found in Luxor. Diabetes originates from the 
Greek word “diabaínein” (διαβαίνειν), “going through” or ‘‘siphon’’, introduced by Aretaeus of 
Cappadocia referring to the excessive amount of fluids passing through the body. He described 
diabetes as “a melting down of the flesh and limbs into the urine”. One millennium ago, 
Avicenna in Baghdad noted the sweetish taste of the urine from patients with the disease and 
divided them into two groups: either young and thin or older and more obese (1, 2). In 1675, 
Thomas Willis added the Latin word “mellitus”, which means sweet or honey, to diabetes and, 
the following century, Matthew Dobbins related the sweet taste to an excess of sugar in the 
urine and blood (3).
The pivotal function of the pancreas and its role in DM was unknown for a long time, even if the 
organ was described as early as 300 BC by the Greek surgeon Herophilus. The name “pancreas” 
was coined from pan (all) kreas (flesh) by the anatomist Ruphos 400 years later (4). Galen of 
Pergamon (AD 138-201), well known for his contribution to the understanding of anatomy, 
suggested that the pancreas served as a protective cushion for the large blood vessels and stomach 
(5). The first understanding of the causes of DM emerged with the development of experimental 
medicine by the end of the nineteenth century. In 1857, Claude Bernard described glycogen as a 
product of glucose metabolism in the liver, postulating that an alteration in this turnover caused 
DM (6). Etienne Lancereaux, a Parisian physician, comparing pancreatic histology in patients 
with and without glycosuria, was the first to report a connection between DM and the pancreas. 
He introduced the term “pancreatic diabetes” (7). In 1869, Paul Langerhans discovered the 
pancreatic islets (8) and others then observed pancreatic and islet abnormalities in deceased 
patients with DM. In 1893, Laguesse named them the islets of Langerhans after their discoverer 
and suggested that these islets produced a secretion involved in the regulation of digestion and 
the combustion of sugar (9). In 1889, Joseph von Mering and Oskar Minkowski made further 
progress. They noted that dogs deprived of the pancreas developed symptoms and eventually 
died of DM and concluded that an agent secreted in pancreas was involved in its aetiology (10).
Glucose-lowering drugs
Insulin
In 1910, Sir Edward Albert Sharpey-Schafer suggested that patients with DM lacked a 
substance, which he called insulin from the Latin word “insula” (island), normally produced 
in the islets of Langerhans (11). Insulin was first isolated in 1921 by the Romanian Professor 
Nicolae Paulescu, who named it pancreatine (12). It was, however, Sir Frederick Grant 
Banting and Charles Herbert Best who became world famous for their work on insulin, 
taking the experiment further by isolating and purifying insulin which, on 11 January 1922, 
they injected into a 14-year-old boy, Leonard Thompson, with DM (13). The following year, 
the Nobel Prize in Physiology or Medicine was awarded jointly to Banting and the head 
of the laboratory, John James Rickard Macleod, “for the discovery of insulin”. Initially, 
         Glucose-lowering and risk assessment in CHD
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Banting refused to accept the prize together with Macleod, claiming that the latter only 
contributed laboratory equipment and arguing that the laboratory assistant Best should be 
the co-recipient. However, Banting and Best experienced some difficulties in their initial 
experiments and were then advised by Macleod to replicate them with better equipment that 
he provided. Banting finally agreed to accept the prize together with Macleod, but he shared 
the money with Best.
Insulin secretagogues and sensitisers
For a long time, insulin was the only pharmacological treatment for DM and this still applies 
to diabetes mellitus type 1. The first alternative was discovered in France by Marcel Janon, 
who treated typhoid fever with sulfonamide and noted that it caused hypoglycaemia (14). 
In 1946, Auguste Loubatières concluded that the compound was an insulin secretagogue. 
Sulphonylureas were introduced in clinical practice during the 1950s. Insulin sensitisers 
in the form of biguanides, including metformin, were developed from the plant Galega 
officinalis. The glucose-lowering effects of metformin were first described in 1929 by Slotta 
and Tschesche but were then forgotten until 1950 when Eusebio Y. Garcia used the drug to 
treat influenza. He noted that the drug, which he called Fluamine “lowered the blood sugar to 
minimum physiological limit”. This aroused the interest of the diabetologist Jean Sterne, who 
was the first to try metformin in patients with DM. He named it “glucophage” (glucose eater) 
and published his results in 1957 (15). Metformin became generally available in Europe back 
in 1958, but it was not approved in the USA until 1994 (16). A massive industrial screening 
of suitable molecules in the late 1990s resulted in another group of insulin sensitisers, the 
thiazolidinediones (or glitazones).
Figure 1. Historical persons of importance in the history of diabetes.
A. Aretaeus and a brief section of his description of diabetes. 
B. Avicenna (Abu Ali Sina) of Baghdad wrote The Canon of Medicine (Al-Qanoon fi al-Tibb, The Laws 
of Medicine), including descriptions of the symptoms and complications of diabetes. 
C. Frederick G. Banting and Charles H. Best. In the background is a page from Banting’s research 
notebook, in which he plans his experimental approach to obtaining the internal secretion of the 
pancreas.
A. B. C.
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Incretins
In the 1960s, it was detected that orally consumed glucose triggers had a more pronounced 
insulin response than intravenous administration (17, 18). The explanation was that hor-
mones, named incretins, that were released in the gut as a response to nutrients, especially 
glucose, stimulated as much as 50-70% of the postprandial beta-cell secretion of insulin 
(19). Several incretin hormones may be active and two of them are the most important: 1) 
the gastric inhibitory polypeptide (GIP) released from the entero-endocrine K cells in the 
proximal small bowel (20) and 2) the glucagon-like peptide-1 (GLP-1) which originates from 
the entero-endocrine L-cells in the distal ileum and colon (21-23). The action of GLP-1 and 
GIP is glucose dependent and rapidly vanishes with decreasing blood glucose. As a result, 
a search was initiated for pharmacological agents that lower glucose by interacting with the 
effects of incretins. One problem was the rapid degradation of GLP-1 and GIP by the enzyme 
dipeptidyl peptidase-4 (DPP-IV) (24, 25). The first agent to reach the market in 2005 was 
exenatide, a synthetic form of exendin-4, a peptide naturally occurring in the saliva of the 
lizard, the Gila monster (Heloderma suspectum; Figure 2), initially isolated by John Eng in 
1992 (26). Exenadin-4 exhibits a 52% amino acid identity with human GLP-1 and displays 
similar functional properties but is resistant to DPP-IV degradation (27).
Definition and classification of diabetes mellitus
The World Health Organisation (WHO) and the American Diabetes Association (ADA) have 
defined DM as a group of metabolic diseases, characterised by hyperglycaemia resulting 
from defects in insulin secretion, insulin action or both, associated with damage to and the 
dysfunction and failure of various organs (28, 29). There are several subgroups of DM and 
the classification is based on the pathogenetic process causing hyperglycaemia (30). 
Figure 2. The Gila monster (Heloderma suspectum), native to the south-western United States and 
north-western Mexico. Copyright: Gary Bell/OceanwideImages.com
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Diabetes mellitus type 1 (T1DM) is characterised by autoimmune beta-cell destruction 
resulting in insulin deficiency. 
Diabetes mellitus type 2 (T2DM) is a more heterogeneous disease with variable degrees of 
impaired insulin secretion and insulin resistance.
Gestational diabetes develops during pregnancy and relates to an increased demand for insulin 
combined with insulin resistance. The majority of women with gestational diabetes revert to 
normal glucose metabolism after delivery, but the risk of subsequent T2DM is 30-60% (31).
Other aetiologies account for a relatively small percentage of DM. They include genetic 
defects in insulin secretion or action and pancreatic exocrine disease.
Glucose tolerance is classified into three categories: 1) normal (NGT); 2) impaired glucose 
metabolism, sometimes referred to as “pre-diabetes”, comprising Impaired Fasting Glucose 
(IFG) and Impaired Glucose Tolerance (IGT) as measured by an Oral Glucose Tolerance Test 
(OGTT), or increased risk of DM as expressed by HbA1c, and 3) T2DM. Since 1965, the WHO 
has published guidelines on the diagnosis of DM on several occasions, most recently in 2006 
(32, 33). Similar guidelines have been issued by an expert group from the ADA (28). In 2003, 
the ADA modified its recommendations, by lowering the boundary for IFG from 6.1 to 5.6 
mmol/L (34). In 2010, the ADA further revised its recommendations, adding HbA1c ≥ 6.5% 
as a diagnostic criterion for T2DM. This recommendation was approved by the WHO in 2011, 
provided that stringent quality tests and standardisation to the international reference values 
were in use and that no condition precluding the accuracy of the measurement was present 
(35). In the absence of symptoms of hyperglycaemia, the diagnosis should be based on glucose 
recordings above the limit on two separate occasions either in the fasting state (Fasting Plasma 
Glucose; FPG), following an OGTT, or based on elevated Haemoglobin A1c (HbA1c). The 
current diagnostic criteria are outlined in Table 1. 
Table 1. Diagnostic criteria of glucose abnormalities according to WHO and ADA.
Intermediate hyperglycaemia DM*
Diagnostic method IFG  IGT Increased risk of DM
Fasting glucose
  WHO
  
  
  ADA
6.1-6.9 
mmol/L
5.6-6.9  
mmol/L
<7.0  
mmol/L
<7.0  
mmol/L
≥7.0  mmol/L
≥7.0  mmol/L
OGTT **
  WHO and ADA
7.8-11.0 
mmol/L
≥11.1 mmol/L
HbA1c 
  WHO
  
  ADA
Not recommended
5.7% - 6.4% (DCCT)
4.7 - 5.5% (Mono S)
39 - 47 mmol/mol (IFCC)
6.5% (DCCT) 
5.6% (Mono S)
48 mmol/mol (IFCC)
6.5% (DCCT) 
5.6% (Mono S)
48 mmol/mol (IFCC)
Random glucose and 
symptoms of hyperglycaemia
≥11.1 mmol/L
*Should be confirmed by repeat testing in the absence of unequivocal hyperglycaemia.
**Venous plasma glucose measured two hours after ingestion of 75 g of glucose in 200 ml of water.
DCCT=Diabetes Control and Complications trial standard; IFCC=International Federation of Clinical Chemistry standard; 
Mono S=Mono Sulphonic acid method
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The diagnosis of T2DM is based on an arbitrary level of glucose, where microvascular 
complications, in particular retinopathy, start to develop in patients with T1DM. As outlined 
in Figure 3, there is usually a period of deteriorating glucose homeostasis lasting several 
years prior to the diagnosis during which symptoms of hyperglycaemia may or may not 
occur. Prerequisites for the development of atherosclerotic macrovascular disease are, 
however, already present during this period. Accordingly, the WHO report and guidelines on 
the management of diabetes, prediabetes and cardiovascular disease issued by the European 
Society of Cardiology and the European Association for the Study of Diabetes underline the 
importance of investigating intermediate hyperglycaemia and that glucose should be regarded 
as a continuous variable in the overall risk assessment of DM as well as cardiovascular 
disease (CVD) (33, 36).
Epidemiology
In 2011, approximately 366 million adults were affected by DM and the disease accounted 
for 4.6 million deaths worldwide. The global increase in DM is rapid and, by 2030, the 
prevalence is projected at 552 million (39). Between 2010 and 2030, there will be a 69% 
increase in the numbers of adults with DM in the developing countries and a 20% increase in 
the developed countries (40). The most substantial increase will be accounted for by T2DM, a 
disease that relates to a sedentary lifestyle and over-nutrition causing overweight and obesity. 
T2DM is responsible for 85-95% of all DM in high-income countries, a proportion that 
may be even higher in low- and middle-income countries (39). T2DM increases the risk of 
developing CVD (41) and serious cardiovascular events are two to four times more common 
in people with T2DM than among those without (42). Despite management improvements, 
CVD remains the leading cause of morbidity and mortality in people with DM (39, 43). 
Consequently, a considerable increase in CVD morbidity is to be expected in the future.
Pathogenesis of diabetes mellitus type 2
T2DM is caused by a combination of reduced insulin sensitivity and secretion. This impaired 
insulin sensitivity is most important in hepatic, muscular and adipose tissue. Insulin resistance 
Prediabetes Frank diabetes
Insulin resistance
Endogenous Insulin
Fasting blood glucose
Macrovascular 
complications
Microvascular 
complications
Time
Years to 
decades Typical diagnosis of diabetes
Postprandial blood glucose
Figure 3. The natural history of impaired glucose tolerance and diabetes mellitus type 2 in relation to 
complications. Adapted and reprinted with permission from references (37, 38).
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is reflected by the impaired suppression of gluconeogenesis in the liver, which increases 
glucagon secretion from the pancreatic alpha cells, adding to fasting hyperglycaemia in 
combination with reduced post-prandial glycogen storage (44-46). The development of T2DM 
is a long-term process initiated by an increase in insulin resistance, which, in combination 
with insufficient insulin secretion, causes post-prandial hyperglycaemia (Figure 3). Due to 
the progressive impairment of the pancreatic beta cells, insulin secretion over time becomes 
too low to keep blood glucose at a normal level even in the fasting state and the disease 
progresses to T2DM. The underlying causes of this process are complex interactions between 
genetic and environmental factors. Among the latter, lifestyle choices, including physical 
inactivity and weight gain, are important (44, 47).  
The beta cell and insulin secretion   
Insulin secretion   
Insulin is produced by the pancreatic beta cells, with glucose as the key regulator. Increasing 
concentrations of glucose activate the secretion of insulin when transported into and 
metabolised within the beta cells. The subsequent increase in adenosine triphosphate (ATP) 
induces the closure of the ATP-sensitive K+ channels, thereby depolarising the beta-cell 
membrane with a concomitant opening of the voltage-dependent Ca2+ channels. The resulting 
influx of Ca2+ triggers the beta cells to release insulin (48, 49). 
The glucose-stimulated insulin response is biphasic (50). Experimental evidence suggests that 
secretory granules are located in two pools with different characteristics, a readily releasable pool 
containing ≤ 5% of all granules, and a reserve pool containing ≥ 95% (Figure 4). Granules in 
Figure 4. Dynamics of insulin secretion. The black lines indicate the dynamics of insulin secretion in the normal state 
and the red lines represent insulin secretion in disease.
A. Profile of glucose-induced insulin secretion, starting with a rapid first and a slower second phase. The first phase 
of insulin secretion reflects exocytosis of a readily releasable pool of granules (RRP). The second phase is due to 
the release of granules from the reserve pool (RP). The mobilisation of granules from the RP into the RRP involves 
ATP-dependent reactions.
B. In IGT, the first phase is slightly impaired because of a decrease in RRP size and/or a partial defect in the exocytotic 
process of granules in this pool, while the second phase is only moderately reduced.
C. In T2DM, the first phase is absent, since the RRP is lost and/or due to a completely defective exocytotic process. 
The second phase is also reduced, probably due to the decreased RP. Reprinted with permission from reference (48). 
ATP=Adenosine TriPhosphate; IGT=Impaired Glucose Tolerance; T2DM=Diabetes Mellitus type 2
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the readily releasable pool are immediately available, while those belonging to the reserve pool 
need to be mobilised before release. The first-phase insulin response involves the plasma-
membrane fusion of granules from the readily releasable pool located at the membrane. 
It peaks within two to five minutes after intravenous glucose administration and lasts for 
approximately ten minutes. Patients with T2DM, as well as those within the IFG range, lack 
this first-phase response (51, 52). The second-phase response, which is evoked by nutrients, 
commences somewhat later and is maintained during the entire hyperglycaemic period. It is 
believed to represent the release of granules from the reserve pool mobilised within the beta 
cell and includes many granules with newly synthesised insulin (48, 49, 51).
 
Insulin signalling 
As schematically depicted in Figure 5, the effect of insulin is mediated by receptors located 
on cellular surfaces. In healthy tissue, this leads to the activation of the phosphatidylinositol 
(PI)-3 kinase pathway (PI3K), which, via endothelial activation, enhances the uptake of 
glucose and nitric oxide (NO) production with concomitant anti-atherogenic effects (e.g. 
vasodilatory, anti-inflammatory and anti-thrombotic). Another important effect of insulin 
is the activation of the mitogen-activated protein kinase (MAPK) pathway, which is pro-
atherogenic, by stimulating cellular growth, proliferation and differentiation. Data indicate 
that the PI3K pathway is down-regulated in the presence of insulin resistance, while the 
MAPK pathway appears to remain sensitive and thereby becomes excessively stimulated. 
This may contribute to cell proliferation, atherogenesis and the activation of inflammatory 
pathways, which may further increase insulin resistance (53, 54).
Figure 5. Insulin receptor signalling. 
IGF=Insulin-like Growth Factor; eNOS=endothelial Nitric Oxide Synthase; ET-1=endothelin-1; 
MAPK=Mitogen-Activated Protein Kinase; NO=Nitric Oxide; PI3K=PhosphatIdylinositol 3-Kinase  
Reprinted with permission from reference (54).
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Beta-cell function and dysglycaemia 
Both beta-cell function and beta-cell mass are impaired in patients with T2DM. To maintain 
normoglycaemia in the presence of insulin resistance, the beta cells up-regulate their insulin 
production and IGT and T2DM do not develop until they fail (44, 55). Autopsy studies reveal 
that subjects with IFG had lost about 40% of their beta-cell volume (56) and corresponding 
reports in T2DM vary between 0% and 63% (55, 57). The normal relation between insulin 
sensitivity and beta-cell function, referred to as the disposition index, is hyperbolic, implying 
that their product is constant (Figure 6). This index expresses the ability of the beta cells to 
compensate for insulin resistance (58, 59).
Dysfunctional beta cells, predicting the future development of T2DM, have been detected 
already in people with NGT (60, 61). In Pima Indians, who have a high prevalence of insulin 
resistance and T2DM, a failing beta-cell function predicts T2DM independently of obesity and 
insulin resistance (62). One distinctive characteristic in individuals who progress from NGT 
to T2DM is a markedly compromised beta-cell function in relation to insulin resistance (63). 
People in the upper tertile of NGT have a 50% decline in beta-cell function and subjects in the 
upper tertile of IGT a 70-80% decline (64) and the beta-cell function continues to deteriorate 
by approximately 4% a year in patients with T2DM, despite glucose-lowering treatment (65). 
Hyperglycaemia has a stepwise-increasing, adverse effect on beta-cell function. The three 
steps have been categorised as follows: 1) glucose desensitisation, a rapid and reversible 
effect of exposure to high glucose concentrations; 2) beta-cell exhaustion, a depletion of the 
readily releasable pool of intracellular insulin without permanent defects; and 3) glucotoxicity, 
non-physiological and potentially irreversible cell damage caused by chronic exposure to 
pronounced hyperglycaemia (66). In addition, hyperglycaemia promotes the accumulation of 
free fatty acid (FFA) metabolites, which inhibits the glucose-induced insulin secretion and 
gene expression (67, 68). Finally, T2DM stimulates the development of amyloid polypeptide 
deposits within the islets of Langerhans. Its relevance for beta-cell function has been debated, 
but recent results from transplantation surgery involving the islets indicates a crucial role in 
the progressive decline in beta-cell function (69).
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Figure 6. The hyperbolic relation between 
insulin sensitivity and beta-cell function. 
Changes in insulin secretion that fully 
ba lance changes in insulin resistance 
result in movement along the hyperbolic 
line and normoglycaemia is maintained. 
Deviation appears when beta-cell function 
is insufficient for the actual insulin 
sensitivity, as in patients with T2DM. 
IGT = Impaired Glucose Tolerance
NGT = Normal Glucose Tolerance
T2DM = Diabetes Mellitus type 2
Adapted and reprinted with permission 
from reference (59).
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Measures of insulin secretion and beta-cell function 
Information on beta-cell function and insulin secretion and sensitivity is commonly obtained 
from mathematically derived expressions relating glucose and insulin concentrations to one 
another. Beta-cell function is often calculated as the homeostatic model assessment beta-
cell function index (HOMA-β; (70) or the proinsulin to insulin (PI/I) ratio (71, 72). These 
simplified approaches do not provide information on the dynamic state of the relationship 
between insulin sensitivity and secretion and this is the reason why many studies include 
blood sampling during tests specially designed to study this question, some of which are 
described below. There is no consensus on a reference method, but, irrespective of the test 
that is chosen, the results should be interpreted in the context of insulin sensitivity and actual 
glucose concentrations.
The glucose clamp, originally described by DeFronzo et al. (73) for the estimation of insulin 
sensitivity, creates hyperinsulinemia by the administration of insulin at a constant rate. The 
amount of glucose infused to maintain plasma glucose at a given level serves as a measure 
of insulin sensitivity. Due to its high reproducibility, it has become the gold standard when 
measuring insulin sensitivity in peripheral tissues and for the evaluation of the second insulin 
secretory response. The disadvantages are that it is a non-physiological test since glucose 
consumption does not normally occur intravenously. Moreover, it is time consuming and 
requires special equipment together with considerable expertise.
The OGTT protocols usually include several blood sampling time points beyond the standard 
fasting and 120 minutes applied for diagnosing IGT and T2DM. The early insulin secretion/
beta-cell function can be estimated as an insulinogenic index (IGI), i.e. the ratio between the 
delta values of insulin and glucose (44, 74). Several formulas have been suggested for the 
expression of insulin sensitivity based on an OGTT (75-77). The OGTT is easy to perform 
and frequently used, but it has been criticised due to low reproducibility.
The frequently sampled intravenous glucose tolerance test (FSIGT) is based on intravenous 
glucose administration and blood sampling during a period of two to four hours. This 
experimental procedure can be used for the estimation of both insulin sensitivity and 
secretion. One advantage is that the injected glucose stimulates the beta cells directly without 
any confounding effects from incretins, gastrointestinal hormones and possible problems 
related to gastric emptying. The disadvantages are that it is non-physiological and technically 
somewhat complicated. A simple measurement of beta-cell function based on an FSIGT is 
to calculate the area under the concentration curve of insulin (AUCinsulin) during the complete 
test or a specific interval. The AUCinsulin represents the amount of insulin acting on the tissues, 
but it does not add any information on the dynamics of the hormone in terms of secretion 
and clearance. Beta-cell function or insulin secretion is often expressed as the acute insulin 
response to the intravenously administered glucose (AIRg), i.e. the mean concentration of 
insulin above the basal level during the peak between two and ten minutes (59). 
Coronary artery disease
Epidemiology
Cardiovascular disease is the main cause of global mortality. In 2008, 17.3 million people 
died of these conditions, which represents one third of deaths worldwide, and the number is 
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expected to increase to 23.6 million people in 2030 (78). In Europe alone, 4.3 million people 
every year die of CVD, representing 48% of the mortality in this region and not only among 
elderly people. It is estimated that 12% of European men and 5% of European women will 
die of CVD before the age of 65 years (79). This burden is not expected to decrease in the 
foreseeable future due to a combination of increased longevity, exposing people to the risk 
of developing CVD, while improved survival in different disease manifestations will leave 
society with more individuals living with these conditions. 
Pathogenesis and clinical manifestations
The most common reason for coronary artery disease (CAD) is atherosclerosis impairing 
the blood flow through narrowing of the coronary arteries in combination with a limited 
capacity to dilate in response to increased demands. Stable CAD may be asymptomatic or 
present itself as angina pectoris, i.e. chest pain due to myocardial ischaemia induced, for 
example, by physical or emotional stress. Acute manifestations of CAD relate to ruptured 
plaques triggering a thrombotic occlusion of the engaged coronary artery and causing an 
acute coronary syndrome (ACS) in the form of either an ST-elevation myocardial infarction 
(STEMI) indicating transmural myocardial damage or a non-ST-elevation myocardial 
infarction (NSTEMI) or unstable angina. The diagnosis of acute myocardial infarction (AMI) 
and unstable angina is confirmed by the rise and fall of cardiac biomarkers, particularly 
troponin, in combination with evidence of myocardial ischaemia in the form of symptoms, 
electrocardiogram (ECG) changes (new ST-T changes or left bundle branch block or the 
development of pathological Q-waves) or imaging signs of loss of viable myocardium or 
new regional wall abnormalities (80). A previous classification of myocardial infarction (MI) 
was based on whether or not there was any development of new pathological Q-waves (81). 
This ECG pattern indicated a transmural infarction, i.e an extensive myocardial cell death 
through the whole of the ventricular wall from endo- to epicardium. The absence of Q-waves 
indicated viable myocardial cells left in the ventricular wall, i.e. a subendocardial infarction.
Coronary revascularisation
Coronary revascularisation, restoring myocardial blood flow, may be performed as coronary 
bypass surgery (CABG) or through a percutaneous coronary intervention (PCI). In patients 
with stable, symptomatic CAD, revascularisation is mainly indicated for the relief of drug-
refractory angina pectoris, but it may also increase longevity in patients with the engagement 
of the left main or proximal left anterior descending coronary arteries. In patients with ACS, 
immediate revascularisation will prevent or limit the extent of myocardial damage, thereby 
reducing mortality and future morbidity (82). 
The dilatation of a coronary stenosis by means of a balloon catheter, PCI, was intro duced 
as an alternative to CABG in 1977 (83). One common complication is restenosis, which 
is the reason this procedure is often supplemented by stenting of the dilatated artery. The 
bare metal stent (BMS) was introduced by the end of the 1980s, reducing the restenosis 
rate from 30-50% to 20-30%. Subsequently, the use of drug-eluting stents (DES) further 
reduced the rate to 5-15% (84, 85). The process of restenosis is initiated by the mechanical 
endothelial damage caused by balloon dilata tion (Figure 7). The inflammatory response to 
the endothelial denudation and subintimal bleeding triggers a cascade of processes involving 
pro-inflammatory cytokines and the activation of leukocytes, platelets and smooth muscle 
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cells (VSMC) in the vessel wall. The activated VSMC stimulate growth factors, causing the 
surrounding cells to proliferate and migrate and to produce extracellular matrix provoking 
neointimal hyperplasia (86). In principle, this represents a physiological, healing reaction 
to injury, which may become overexpressed, resulting in a restenosed vessel usually within 
three to six months after the PCI (85). 
Coronary artery disease and hyperglycaemia
The connection between DM and coronary heart disease (CHD) was first noted by Seegen, 
who, in 1864, drew attention to the occurrence of angina pectoris in patients with DM (87). 
Figure 7. Mechanisms of restenosis after a PCI. 
Intravascular ultrasound images of the various stages of CAD. The outer border of the ves-
sel is indicated in green, the lumen in red and the coronary stent in yellow. A sche-
matic presentation of the different processes is shown to the right of these images. 
ADMA=Asymmetric DiMethylArginine; ECM=Extracellular Matrix; MMPs=Matrix MetalloProteinases; 
mTOR=mammalian Target Of Rapamycin; PAI-1=Plasminogen Activator Inhibitor 1; PCI=Percutaneous 
Coronary Intervention; TNF=Tumour Necrosis Factor; VSMC=Vascular Smooth Muscle Cells 
Reprinted with permission from reference (85).
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In 1888, Mayer complained that “… those who have occupied themselves with investigating 
the pathology of diabetes seem to have given their chief attention to the examination of 
those organs, which experimental physiology had shown to be more particularly involved 
in its production” (88). The short life span of people with DM and, for that reason, the low 
incidence of CHD may explain the low level of interest in the combination. The relationship 
between CHD and DM received more attention following the discovery of insulin, increasing 
longevity and the concomitant risk of developing cardiovascular complications (89-91).
In 1999, Norhammar et al. (92) were among the first to describe that hyperglycaemia at 
admission for an ACS worsens the prognosis, a finding subsequently confirmed in several other 
studies (93, 94). A systematic overview by Coutinho et al. (95) indicated that hyperglycaemia 
is a continuous risk factor from fasting or postload glucose levels below the diagnostic 
threshold for T2DM. Accordingly, hyperglycaemia is a marker of poor prognosis, but it 
may also be one of the underlying mechanisms contributing to the increased cardiovascular 
risk, making it of interest to study glucose metabolism in patients with CAD in more detail. 
The combination of AMI and established T2DM is common, with a prevalence of ≥ 20% 
(96). Moreover investigations of patients with acute and stable CAD without previously 
known glucose abnormalities by means of an OGTT revealed that about 30% had IGT and 
another third undiagnosed T2DM (97-99). The presence of glucose perturbations worsens the 
prognosis by increasing the risk of future cardiovascular morbidity and mortality in patients 
with both acute and stable CAD (100-103). Further investigations of patients with ACS 
revealed that their insulin resistance, expressed as the HOMA index, was somewhat high but 
not different from that of age- and gender-matched controls. The patients did, however, have 
a more pronounced beta-cell dysfunction, as demonstrated by a higher proinsulin/insulin 
ratio within each glucose category (NGT, IGT and T2DM) and a deteriorating IGI (104, 105).
Hyperglycaemia and vascular dysfunction
Hyperglycaemia impairs endothelium-dependent relaxation by reducing the bioavailability 
of NO and other vasodilators concomitant with the increased synthesis of vasoconstrictors 
such as endothelin-1(106). This process is presumed to be initiated by oxidative stress 
triggered by hyperglycaemia activating superoxide-producing enzymes such as nicotinamide 
adenine dinucleotide phosphate (NADPH). The elevated superoxide levels stimulate the 
production of advanced glycation end products (AGEs) with an adverse impact on cellular 
function. The AGEs also contribute to the production of oxygen-derived free radicals. As 
depicted in Figure 8, four different pathways triggered by hyperglycaemia appear to be 
involved in the overproduction of superoxide anions by the mitochondrial electron-transport 
chain as the common denominator (107). Important implications of hyperglycaemia are 
inflammatory activation mediated by nuclear factor κ-B (NFκB), the oxidation of plasma low 
density lipoproteins (LDL) and the promotion of a prothrombotic state by platelet activation, 
thrombin generation in combination with impaired fibrinolysis due to the reduced synthesis of 
plasminogen activator inhibitor-1 (PAI-1) (106, 108, 109).
Revascularisation with PCI in diabetes mellitus type 2
Revascularisation by means of PCI is less rewarding in patients with T2DM than in those 
without (110). Even a modest increase in blood glucose at the time of the procedure is 
associated with increased long- and short-term mortality (111, 112). Further, the restenosis 
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rate is much higher in patients with T2DM (113, 114). After a PCI with BMS, ≥ 30% of 
patients with T2DM will develop a restenosis compared with ≤ 20% of their counterparts 
without DM (115). The subsequent high demand for repeat revascularisation exposes 
patients with T2DM to an increased risk of periprocedural complications (116). Although the 
introduction of DES reduced the need for target lesion revascularisation, the restenosis rate 
remains higher among patients with T2DM (117, 118). 
The marked propensity for restenosis in T2DM may relate to processes induced by 
hyperglycaemia, further enhanced by inflammatory activation (119, 120). Interestingly, the 
increased production of the vasoconstrictor thromboxane A2 correlates to fasting plasma 
glucose and can be restored to normal by strict glycaemic control. Moreover, abnormalities 
in the extracellular matrix relating to the reduced production of matrix-associated heparan 
sulphate, a potent inhibitor of VSMC proliferation and AGE accumulation in the vascular 
tissue, increases with exposure to glucose, stimulating VSMC proliferation and abnormal 
matrix production and thereby the propensity for restenosis (121). 
Figure 8. Potential mechanism by which hyperglycaemia-induced mitochondrial superoxide overpro-
duction activates four pathways of hyperglycaemic damage.  
AGE=Advanced Glycation End products; DAG=DiAcylGlycerol; ET-1=Endothelin-1; eNOS=endothelial 
Nitric Oxide Synthetase; GAPDH=GlycerAldehyde 3-Phosphate DeHydrogenase; 
NAD(P)H=NicotinAmide adenine Dinucleotide Phosphate-oxidase; NF-κB=Nuclear Factor κ-B; 
ROS=Reactive oxygen species; TGF-β1=Growth Factor-β1; PAI-1=Plasminogen Activator Inhibitor-1; 
PKC=Protein Kinase C
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Glucose control
Short term 
Attempts have been made to improve the prognosis of patients with T2DM and AMI by 
means of strict glucose control. In the Diabetes Glucose and Acute Myocardial Infarction 
study (DIGAMI), these patients were randomised to an acute insulin-glucose infusion 
instituted soon after the onset of symptoms and followed by multi-dose insulin therapy 
aiming at stable normoglycaemia or to conventional glucose-lowering therapy without any 
predefined glucose targets (122). After 3.4 years of follow-up, the insulin-based glycaemic 
control had reduced the mortality rate to 33% in the intensively treated group compared with 
44% in patients belonging to the control group, a relative reduction of 28% (123). Subsequent 
studies were unable to confirm these findings. The DIGAMI 2 study was designed to resolve 
the question of whether the reduction in mortality was due to the acute administration of 
an insulin-glucose infusion or to improved metabolic control after hospital discharge. The 
prognosis among patients in the insulin infusion followed by insulin arm did not differ from 
that in patients randomised to the acute insulin infusion followed by conventional therapy 
or in patients in the control arm treated at the discretion of the attending physician (124). 
Likewise, the Australian Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) 
study did not show a mortality reduction in the intensively treated arm (125). Interestingly, 
in HI-5, mortality was lower in a subgroup of patients with tight glycaemic control (mean 
glucose ≤ 8 mmol/L), regardless of whether the target was obtained by means of insulin or 
other glucose-lowering agents (125).
Apart from hyperglycaemia, the induction of hypoglycaemia is a concern in patients 
hospitalised with an ACS. Hypoglycaemia enhances catecholamine release which may cause 
arrhythmias (126) and aggravate myocardial ischaemia (127). Additionally fluctuations in 
glucose may also trigger the release of catecholamines further aggravating the negative 
effects of myocardial ischaemia (128) and studies in patients with T2DM have demonstrated 
that markers of oxidative stress are independently associated with the mean amplitude of 
glycaemic excursions (129). One possible cause could be that hyperglycaemic spike-evoked 
oxidative stress activates pathways involved in the pathogenesis of diabetes complications, 
particularly increased superoxide production at the mitochondrial level (130). There are, 
however, diverging results in this field (131). This underlines the importance of diminishing 
untoward variability while remaining within the narrow euglycaemic range (132, 133).
Glucose monitoring
Current insulin titration algorithms are based on isolated glucose measurements which, 
although frequent, provide a scattered picture of the overall glycaemic situation, including 
the possibility of missing rapid shifts in blood glucose. Patients in coronary care units (CCU) 
are not subjected to the same supervision as, for example, those admitted to intensive care 
units and fear of the induction of hypoglycaemia has been reported as an obstacle to the use 
of sufficient amounts of insulin to reach targeted glucose levels in patients with AMI (124, 
125). Moreover, insulin algorithms are inconvenient for patients as they require frequent 
blood sampling (134), increasing the workload and thereby the costs (135). For this reason, 
reliable glucose monitoring equipment with an on line presentation of the results may be 
an important tool in future attempts finally to test the still unproven hypothesis that intense 
glucose control is prognostically beneficial for T2DM patients with AMI.
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Long term
Improved long-term glucose control may have a beneficial effect on cardiovascular mortality 
and morbidity. In the UK Prospective Diabetes Study (UKPDS), intensive glucose control 
in patients with newly detected T2DM, based on either oral glucose-lowering drugs or 
insulin, reduced microvascular complications. Moreover, metformin was successful in 
reducing myocardial infarction by 33% (p=0.005) and mortality by 27% (p=0.002) (136). 
These findings are, however, not unchallenged and intensive glycaemic control has failed 
to show any significant reduction in cardiovascular outcomes or improve the prognosis in 
trials performed with different combinations of glucose-lowering agents in high-risk patients 
with T2DM established for several years (137-139). It may be that long-term, intensive 
glucose lowering is possibly more rewarding if instituted early and/or that the ideal agent for 
accomplishing glucose control is yet to be found (140, 141). 
Incretins
The gut-derived hormones called incretins, GLP-1 and GIP, exert glucose-dependent 
insulinotropic actions on the beta cells, resulting in low secretion in the fasting state and 
a rapid post-prandial rise, which provides effective protection from hypoglycaemia (142-
144). Both hormones exert their effects via the activation of their respective trans-membrane 
G protein-coupled receptors (GPCR). The GIP receptor is predominantly expressed on 
pancreatic beta cells and to a lesser extent in adipose tissue and the central nervous system. 
The GLP-1 receptors are found on a range of tissues including pancreatic alpha and beta 
cells, the kidneys, lungs, central and peripheral nervous system and the gastrointestinal tract 
(145-147). In the cardiovascular system, they have been further localised in cardiomyocytes, 
endothelial and endocardial cells and in aortic smooth muscle cells from mice (148). This 
ubiquitous presence of receptors suggests that incretins may perform other biological roles 
in addition to releasing insulin (145, 147). The active form of GLP-1 is only present in the 
circulation for one to two minutes because of rapid degradation by the DPP-IV enzyme  which 
also degrades GIP (24, 25). Since the metabolites do not activate the GLP-1 receptor, they 
lack insulinotropic action, which limits the bioavailability of GLP-1 (149). In experimental 
studies, GLP-1 and GLP-1 analogues have been associated with the expansion of the beta-
cell mass via the stimulation of beta-cell replication, the proliferation and promotion of islet 
cell neogenesis from precursor ductal cells and the inhibition of apoptosis (150-154).
Incretins in T2DM
In patients with T2DM, the incretin effect may be reduced or even lost (155) due to reduced 
incretin secretion or action. Until recently, the GLP-1 secretion was considered to be impaired, 
but recent data indicate that it is probably preserved (156, 157). The conflicting results may 
relate to the population being studied, as it seems as though the degree of insulin resistance 
and obesity is of importance for the secretion (156, 158). The diminished insulinotropic 
action of GIP, and to some extent also of GLP-1, has been demonstrated in patients with 
T2DM, although supraphysiological levels of the latter still increase insulin secretion 
(159). In addition to the insulinotropic effects, GLP-1 inhibits the secretion of glucagon, 
hepatic glucose production and gastrointestinal motility, in turn promoting satiety leading to 
reduced food intake and weight loss (Figure 9) (145, 160). In patients with T2DM, GLP-1 
receptor agonists restore the first-phase and augment the second-phase insulin response 
(161), indicating improved beta-cell function when used alone (162) or in combination 
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with metformin and/or sulphonylurea (163, 164). Increasing the levels of incretins for the 
treatment of patients with IGT or T2DM seems logical, not the least when dealing with newly 
detected glucose perturbations in patients with ACS in whom beta-cell dysfunction appears 
to be an early and important pathophysiological aberration.
GLP-1 receptor agonists and DPP-IV-inhibitors 
A great deal of effort has focused on amplifying the effects of GLP-1 for therapeutic 
applications and two concepts have been developed; the GLP-1 receptor agonists (incretin 
mimetics) and DPP-IV inhibitors (incretin enhancers) (165, 166). At present, there are two 
GLP-1 receptor agonists on the market, exenatide (Byetta®) and liraglutide (Victoza®), and 
several are under development (albiglutide, tasboglutide, dulaglutide, lixisenatide, exenatide 
long-acting release (LAR) and CJC-1134-PC). The GLP-1 receptor agonists, which require 
subcutaneous administration, reduce HbA1c by 0.7-1.7% (DCCT standard) in patients 
with T2DM compared with placebo (165). Several DPP-IV inhibitors, compounds that 
Figure 9. Effects of the GLP-1 system in T2DM. Reprinted with permission from reference (155).
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reduce serum DPP-IV activity by ≥ 80% thereby delaying the degradation of GLP-1, are 
available; sitagliptin (Januvia®), vildagliptin (Galvus®), saxagliptin (Onglyza®), linagliptin 
(Tradjenta®) and alogliptin (Nesina®) or in the later stages of development (denagliptin, 
melogliptin, carmegliptin, dutogliptin, gosogliptin). They can be administered orally with 
some inhibition maintained for 24 hours after a single dose (167) and reduce HbA1c by 0.5-
0.9% (DCCT standard) compared with placebo (165).
Cardiovascular effects 
GLP-1 has wide-ranging cardiovascular actions including the modulation of heart rate, blood 
pressure, endothelial function and myocardial contractility (168-173). The GLP-1 agonist 
exenatide lowers blood pressure in patients with T2DM (174). GLP-1 infusion has been 
demonstrated to induce endothelial-dependent vasodilation in patients with CAD and T2DM 
(175) and it generated a trend towards improved systolic and diastolic myocardial function 
(176), an effect seen in patients both with and without T2DM (177). Ten patients with AMI and 
heart failure who were exposed to a GLP-1 infusion improved their left ventricular function 
after successful PCI (178) and GLP-1 infusion reduced the need for inotropic support after 
CABG (179). This ability to improve myocardial contractility and coronary blood flow is 
possibly independent of the activation of the GLP-1 receptor since it has been attributed to 
the gluco-metabolically inactive metabolite GLP-1 (9-36) amid (148, 180, 181). The GLP-1 
agonist exenatide also reduces reperfusion injury and thereby potentially infarct size (182). 
In clinical trials recruiting patients with T2DM, GLP-1 agonists had positive effects on blood 
lipids, the lowering of total and LDL cholesterol, a finding that requires further verification 
since it may have been related to GLP-1-induced weight loss (173).
         Glucose-lowering and risk assessment in CHD
27
AIMS
1. To test the hypothesis that tight, insulin-based glucose control will reduce the rate of 
restenosis after a percutaneous coronary intervention in patients with diabetes mellitus 
type 2
     (Study I)
2. To validate the oral glucose tolerance test for the detection of glucose disturbances in 
patients with acute coronary syndromes 
     (Studies II-III)
3. To evaluate the accuracy of microdialysis as a technique for continuous monitoring of 
glucose levels in patients in coronary care units
     (Study IV)
4. To test the hypothesis that the DPP-IV inhibitor sitagliptin improves beta-cell function in 
patients with acute coronary syndromes and newly detected glucose disturbances
     (Study V)
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PATIENT MATERIAL AND METHODS
Patients and protocols
Studies I-V are based on four different sets of patient material; the IDA (Insulin Diabetes 
Angioplasty) Study (I), the GAMI (Glucose metabolism in Acute Myocardial Infarction) Study 
(II), the Microdialysis Study (IV) and the BEGAMI (BEta-cell function in Glucose abnormalities 
and Acute Myocardial Infarction) Study (III and V) recruiting patients between 1998 and 2010 
(Table 2).
Study I 
Insulin Diabetes Angioplasty (IDA)
Hypothesis: Study I tested the hypothesis that intensified, insulin-based glucose control will 
reduce the propensity for restenosis.
Patients: A detailed description of patient recruitment is presented in Figure 10. Patients at 
Karolinska University Hospital in Stockholm and Sahlgrenska University Hospital in Gothenburg 
with established T2DM and who had been accepted for revascularisation with PCI were eligible 
for inclusion. The exclusion criteria were AMI within 48 hours before the intervention, inability 
to participate for physical or psychological reasons or residence outside the catchment area. 
Recruitment commenced in March 1999 and was prematurely stopped in March 2003 due to a 
slow inclusion rate and a change in treatment practice introducing drug-eluting stents. 
Table 2. Summary of essential characteristics in Studies I – V.
Number of 
participants
Recruitment 
period
Glucose 
abnormality
Study design Intervention Endpoint
Study I
IDA
82 March 1999- 
March 2003
T2DM PROBE Intensive, 
insulin-
based 
glucose 
control
Restenosis 
after six 
months
Study II
GAMI
172 Nov 1998-
Dec 2000
NGT, IGT, 
T2DM
Prospective
-
Concordance 
of OGTT 
results
Study III
BEGAMI
79 May 2008-
Sept 2010
IGT, T2DM Randomised,
prospective
- Classification 
of T2DM
Study IV
Micro-
dialysis 
14 Feb-May 
2009
NGT, IGT, 
T2DM
Prospective
-
Concordance 
of glucose 
measurements
Study V
BEGAMI
71 May 2008-
Sept 2010
IGT, T2DM Randomised, 
prospective, 
controlled,
double-blind
Sitagliptin/
placebo
Beta-cell 
function after 
12 weeks
IGT=Impaired Glucose Tolerance; NGT=Normal Glucose Tolerance; PROBE= Prospective, Randomised with 
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Protocol: Following stratification according to the type of PCI (elective or acute), the 102 
patients were randomised to either intensive insulin-based (I group) or standard (C group) 
glucose-lowering therapy. The final group in whom restenosis could be assessed consisted of 
82 patients (I group=39; C group=43). Follow-up visits were scheduled two weeks and one 
and three months after the index PCI. A coronary angiogram was performed after six months. 
In the presence of symptoms indicating restenosis, an angiogram could be performed prior 
to this occasion. Patients without an angiographically demonstrable restenosis at that time 
were reinvestigated at six months, while an already verified restenosis was accepted without 
further angiography.
Glucose control: In elective patients randomised to the intensive group, efforts to optimise 
glycaemic control were initiated three weeks prior to the PCI to be continued during the 
complete study period. The aim was to achieve HbA1c of < 6.5% (Mono S), fasting blood 
glucose (FBG) of 5-7 mmol/L and blood glucose before meals of < 10 mmol/L. The protocol 
specified treatment with fast-acting meal insulin three times daily and long-acting insulin at 
bedtime.
Following randomisation, patients hospitalised with unstable angina were brought to the best 
possible glucose control as quickly as possible by means of a glucose-insulin infusion aiming 
at blood glucose of 4-9 mmol/L. The infusion continued for at least 12 hours after the PCI. 
After termination of the infusion, these patients followed the treatment outlined for elective 
patients during the six-month study period. Control patients continued ongoing glucose-
lowering treatment (insulin, oral agents or combinations). Any change in their diabetes 
medication was at the discretion of the attending physician, as was the glucose target.
PCI: Balloon angioplasty and coronary stenting were performed according to standard at the 
time of the study. A ≥ 50% luminal diameter reduction was defined as significant. A BMS 
Figure 10. Patient flow in Study I. PCI=Percutaneous Coronary Intervention
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was applied if the vessel diameter was ≥ 3 mm, if the balloon dilatation was suboptimal or 
if it caused dissection. After stent implantation, the goal for the intervention was a residual 
stenosis of < 20% of the reference diameter measured on line with Quantitative Coronary 
Angiography (QCA) in combination with TIMI 3 flow. If the lesion length was > 15 mm and/
or the vessel diameter < 3 mm, a residual stenosis of < 50% at the dilatated site measured on 
line with QCA was accepted as successful in order to avoid multiple or long stents.
Endpoint: The primary endpoint was restenosis after six months analysed off line with 
the Cardiovascular Measurement System (Medis, Leiden, The Netherlands) by two 
interventionists blinded to the randomised intervention. Matched angiographic views were 
obtained for each patient before and after the procedure and at the six-month follow-up. 
Angiographic restenosis was defined as a ≥ 50% diameter stenosis. 
Study II 
Glucose metabolism in Acute Myocardial Infarction (GAMI)
Aim: To evaluate the accuracy of an early OGTT in relation to infarct type.
Patients: The material comprised the 172 patients with a recorded ECG from the GAMI trial 
(total n=181) that investigated the prevalence of previously unknown glucose abnormalities 
in patients with AMI admitted to Karolinska University Hospital in Stockholm and Västerås 
Hospital between November 1998 and December 2000 (97). The exclusion criteria were age 
> 80 years, serum creatinine of ≥ 200 μmol/L and living outside the catchment area. 
Protocol: The patients were classified as having a transmural MI defined as the presence of 
a Q-wave in at least two contiguous leads or a subendocardial MI in the absence of such a 
pattern. During hospitalisation, FBG was measured on day one to four, a 75g standardised 
OGTT was performed on day four or five and at an outpatient visit three months later. 
Endpoint: The primary endpoint was the concordance between the outcome of the OGTT 
performed prior to discharge and three months later.
Study IV
Continuous glucose monitoring in ACS
Aim: To evaluate the accuracy of a microdialysis catheter as a tool for safely and accurately 
monitoring of glucose levels.
Patients: Fourteen patients with ACS or congestive heart failure admitted to the CCU at 
Karolinska University Hospital in Stockholm between February and May 2009. The exclusion 
criteria were known allergy to dalteparin or difficulty obtaining venous access.
Protocol: A microdialysis catheter (CMA 64 IView, CMA Microdialysis AB, Solna, Sweden) 
was inserted in an arm vein for a maximum of three days. Microdialysis fluid consisting 
of saline and dalteparin (150 IU/mL) was transfused at 1 μL/min and collected in vials in 
eight-minute fractions. Reference plasma glucose was measured in blood obtained from 
a peripheral venous catheter in a contralateral arm vein in the middle of the eight-minute 
fraction. Eight pairs of samples were collected during one hour, a procedure that was repeated 
daily for three days.  
Endpoint: The primary endpoint was the concordance between plasma glucose obtained via 
the microdialysis catheter and standard, laboratory-based measurements.
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Studies III and V 
BEta-cell function in Glucose abnormalities and Acute Myocardial Infarction 
(BEGAMI)
Hypothesis/aim: Study III aimed to compare an OGTT with FPG and HbA1c as methods for 
detecting glucose abnormalities in patients with ACS, while Study V tested the hypothesis 
that the DPP-IV inhibitor sitagliptin improves beta-cell function in patients with ACS and 
newly diagnosed glucose disturbances. In addition, the safety of early institution of sitagliptin 
in this patient category was studied. 
Patients: BEGAMI recruited patients with ACS without previously known glucose 
perturbations at the CCU at Karolinska University Hospital and Danderyd Hospital in 
Stockholm. The exclusion criteria were age < 18 years, impaired renal function, BMI ≥ 
34 kg/m2, heart failure (NYHA III-IV), inability to follow the study protocol or a planned 
coronary revascularisation.
Patient recruitment started in May 2008 and follow-up was completed in December 2010. As 
shown in Figure 11, a total of 174 patients underwent the screening OGTT and 75 (43%) of 
them had a normal glucose tolerance, 63 (36%) IGT and 36 (21%) T2DM. Thirteen patients 
declined participation and seven were randomisation failures, leaving 79 patients with IGT or 
T2DM and a recorded HbA1c value for the analysis in Study III. Of these patients, 39 were 
randomised to sitagliptin and 40 to placebo. Study V is based on the 71 patients with complete 
follow-up data returning to the clinic after 12 weeks (Figure 11).
Figure 11. Patient flow in Studies III and V. 
CABG=Coronary Artery Bypass Grafting; FSIGT=Frequently Sampled Intravenous Glucose Tolerance 
Test; IGT=Impaired Glucose Tolerance; NGT=Normal Glucose Tolerance; OGTT=Oral Glucose Tolerance 
Test; T2DM=Diabetes Mellitus type 2
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Protocol: The protocol for Studies III and V is outlined in Figure 12. A screening OGTT was 
performed before hospital discharge four days after admission at the earliest or at a scheduled 
outpatient visit within three weeks. Patients with IGT or T2DM were eligible and returned to 
the clinic the following day for a FSIGT. When this was completed, they were randomised to 
receive 100 mg sitagliptin (Januvia™, Merck Sharp & Dohme AB) or a matching placebo once 
daily in double-blind fashion. All patients were given structured lifestyle advice. They were 
provided with a glucometer and instructed to check glucose regularly during the study period. 
The OGTT and FSIGT were repeated on two subsequent days after 12 weeks of follow-up.
Endpoints: The primary endpoint in Study III was the concordance between glucose 
characterisation with OGTT, FPG and HbA1c. The primary endpoint in Study V was an 
improvement in beta-cell function measured by means of the IGI (ΔI30/ΔG30) obtained from 
the OGTT. Secondary endpoints were 1. Improvement in glucose tolerance tested with an 
OGTT and 2. Improvement in GLP-1 independent beta-cell function measured as the ΔAIRg 
during the FSIGT.
Study procedures
Microdialysis
In Study II, a microdialysis tube, inserted into an arm vein, was used as “an artificial blood 
capillary” in order to monitor blood glucose. The catheter had a double-space lumen (Figure 
13). A perfusion fluid was infused at a constant rate through the catheter in the space between 
the inner tube and the outer dialysis membrane. Glucose in the blood diffused across the 
catheter membrane into the perfusion fluid, which then entered into the inner tube to be 
collected in micro vials for analysis.
Figure 12. A schematic presentation of the study protocol in Studies III and V. 
ACS=Acute Coronary Syndrome; AIRg=Acute Insulin Response  to glucose; FSIGT=Frequently Sampled 
Intravenous Glucose Tolerance Test; GLP-1=Glucagon-like peptide-1 IGI=Insulinogenic Index; 
OGTT=Oral Glucose Tolerance Test; R=Randomisation
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OGTT
The OGTTs in Studies II, III and V were performed according to WHO recommendations 
(183). Following 12 hours of overnight fasting, 75 g of glucose dissolved in 200 ml of water 
was administered orally. A peripheral venous catheter was inserted into an antecubital vein for 
blood sampling. In Study II, venous blood samples and capillary blood glucose measurements 
were obtained prior to and 15, 30, 60 and 120 minutes after the glucose ingestion. In Studies III 
and V, venous blood samples for the analysis of glucose and insulin were obtained prior to and 
30, 60 and 120 minutes after the glucose ingestion. Blood for the analysis of insulin was kept 
on wet ice until centrifugation, which was performed within one hour at 2,000g for 20 minutes. 
FSIGT
The FSIGTs in Study V were performed after 12 hours of overnight fasting. Two peripheral 
venous catheters were inserted into contralateral antecubital veins; one for blood sampling 
and one for glucose injection. A basal sample was drawn at -5 min. At 0 min, glucose 
(300 mg/kg) was injected for two minutes. Blood samples were then collected at 2, 5, 7, 
10, 20, 30, 60 and 120 minutes for the analysis of glucose and insulin. Blood for the analysis 
of insulin was kept on wet ice until centrifugation, which was performed within one hour at 
2,000g for 20 minutes. 
Laboratory analyses
Glucose was immediately analysed in capillary whole blood using a photometric technique 
(Hemocue® AB, Ängelholm, Sweden) in Studies I-III and V. The values in Studies III and 
V were recalculated to venous plasma glucose. In Study IV, venous plasma glucose was 
analysed at the end of the study on cool-handled blood stored as plasma at -70°C using a 
glucose oxidase-based method (Konelab 20 automated analyser, Thermo Clinical Labsystems 
Oy, Vantaa, Finland).
HbA1c in Studies I and II was analysed in a core laboratory by high-performance liquid 
chromatography (Department of Laboratory Medicine, Malmö University Hospital, Sweden) 
on capillary blood applied on filter paper with an upper normal limit of 5.3% (Mono S; 
Boehringer Mannheim Scandinavian AB, Bromma, Sweden) and, in Studies III (Mono S) and 
V (IFCC), with ion-exchange high-performance liquid chromatography (Bio-Rad Laboratories, 
Hercules, CA, USA).
Figure 13. The microdialysis catheter, IView. See the text for further explanation.
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Plasma insulin in Studies II and V was analysed after the termination of the study from plasma 
stored at -70°C and quantified with commercially available, specific immunoassays (DAKO 
Ltd, Cambridgeshire, UK).
Proinsulin in Study V was analysed using an ELISA kit (Mercodia AB, Uppsala, Sweden).
Calculations
In Studies II and V, insulin resistance was calculated as homeostatic model assessment insulin 
resistance (HOMA-IR) according to Matthews (70).
HOMA-IR=Fasting Glucose (mmol/L) x Fasting Insulin (mU/L)/22.5
In Study V, beta-cell function was calculated as the insulinogenic index (IGI) (74) as follows: 
IGI=Δinsulin0–30/Δglucose0–30
and Acute Insulin Response to glucose (AIRg) as the 
incremental area under the curve by using the trapezoidal rule from 0 to 10 minutes.
The glucose disappearance constant (Kg) was calculated as the slope of the natural logarithm of 
the two glucose samples taken at 10-20 min
Kg=[Δ ln plasma glucose/ Δ min] x 100
Statistics
Studies I-V
Descriptive statistics were presented as follows, unless otherwise stated: continuous variables 
were expressed as the median and lower and upper quartiles and Wilcoxon’s random test was 
used for differences between groups. Categorical variables were expressed as numbers and 
percentages and analysed using Fisher’s exact test.
The assumptions behind the power calculation in Study I were a restenosis rate of 30-40% and 
that a reduction to 25% would be clinically meaningful. Based on this, a number of 170 patients 
in each group was required for a significance level of 5% and a power of 80%.
Univariable predictors of restenosis were identified by logistic regression analysis. Multiple 
logistic regression analysis was performed with restenosis after six months as dependent 
variable, while candidate predictors defined as variables with a p-value of ≤ 0.2 were entered 
into a best subset selection.
A two-tailed p-value of < 0.05 was considered statistically significant.
Statistical analyses were performed using SAS software version 9.1.3 (Studies I, II and IV) or 
9.2 (Studies III and V). 
Study II
The concordance rates of glucose categories between repeated OGTTs were calculated as 
weighted Cohen’s kappa.
Study IV
Congruence between glucose measurements was evaluated as the mean and median absolute 
difference and the mean and median absolute relative difference between each matched 
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pair of microdialysis and plasma glucose measurements. In addition, data were presented 
according to the ISO-15197 criteria, including the proportion of paired data points falling 
within ±0.8 mmol/L for a reference glucose level (in the present material plasma glucose) of 
< 4.2 mmol/L or within ±20% for reference glucose levels of ≥ 4.2 mmol/L (184).
To test clinical accuracy, all matched points from all patients were plotted on a Clarke error 
grid where the relevance of differences between reference and measured values is taken into 
account. The plasma glucose was used as the reference value and plotted on the x-axis against 
microdialysis values plotted on the y-axis (185).
Study V
The sample size calculation was based on a previous study (105), which estimated the mean 
and standard deviation of the IGI as 50 ± 35 (pmol/mmol). To detect an increase of 50% 
between the two treatment groups at a 5% level of significance with 80% power using a 
two-tailed t-test, a sample size of 64 patients was considered sufficient. An additional 5% 
was added to enable the use of non-parametric methods and cover for the potential loss of 
patients, resulting in a total sample size of 70 patients. The change in beta-cell function was 
calculated by an analysis of covariance (ANCOVA), using the linear model with terms for 
treatment (sitagliptin/placebo) and baseline IGI as covariates. 
Ethical considerations
The studies were performed in accordance with good clinical practice guidelines (ICH-GCP) 
and followed the recommendations of the Helsinki Declaration. The separate protocols were 
approved by the Regional Ethical Review Board in Stockholm and all the patients provided 
written and oral informed consent prior to study participation.
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RESULTS
Study I
Restenosis in T2DM
As can be seen in Table 3, there were no major differences between patients in the I and C 
groups at randomisation.
Table 3. Clinical characteristics of the patients in Study I. Continuous variables are presented 
as the median and lower and upper quartiles (quartile 1; quartile 3) and categorical variables 
as numbers (n) and percentages (%), unless otherwise stated.
Variable I group (n=39) C group (n=43)
Baseline characteristics
   Age (years) 66 59;72 62 59;68
   Gender (male) 74 76
Previous medical history
   Smoking 28 72 26 60
   Hypertension 23 59 28 65
   Hyperlipidemia 30 77 30 70
   Angina pectoris 36 92 41 95
   Myocardial infarction 19 49 17 40
Treatment at randomisation
   Aspirin 34 87 40 93
   Beta blockers 33 85 38 88
   ACE or ARB inhibitor 12 31 21 49
   Diuretics 13 33 7 16
   Lipid-lowering agent 32 82 28 65
Diabetes
   Duration (years) 6.4 4.3;12.1 6.5 2.7;12.7
   Fasting blood glucose (mmol/L) 7.0 6.8;8.5 7.3 6.5;8.7
   HbA1c (%; Mono S method) 6.5 5.8;7.7 6.5 5.8;7.6
Glucose-lowering treatment 
  Non pharmacologic treatment 4 10 3 7
  Acarbose 3 7 1 2
  Sulphonylureas 19 49 24 56
  Metformin 12 31 19 44
  Insulin 17 44 15 35
Treatment at the index PCI
   Ticlopidine/clopidogrel 36 92 37 86
   Stent (BMS) 35 90 34 81
   GP IIb/IIIa inhibitor 16 41 14 33
ACE=Angiotensin Converting Enzyme; ARB=Angiotensin II Receptor Blocker, BMS=Bare Metal Stent; PCI=Percutaneous Coronary Intervention
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At the follow-up six months after the initial PCI, there was no significant change in glucose 
control in either of the two groups. The FBG increased by 0.2 mmol/L in the I group and 
decreased by 0.3 mmol/L in the C group (p=0.3) and HbA1c decreased by 0.2% in the I group 
and 0.05% in the C group (p=0.2).
Descriptive variables from the index PCI and follow-up angiography are presented in Table 4. 
Regardless of randomised treatment, the percentage of target lesion restenosis was similar in 
both groups (I group 41% vs. C group 44%; p=0.8), as was the percentage of renewed target 
vessel intervention. 
As the study groups did not differ in terms of achieved glucose control and restenosis 
rate, an analysis looking for predictors of restenosis within the complete patient cohort 
was performed. Relevant predictors are shown in Figure 14. Following adjustments in a 
multivariable analysis, the remaining two significant predictors of restenosis were FBG at 
randomisation (OR 1.4, 95% CI 1.1-1.9; p=0.015) and previous MI (OR 8.0, 95% CI 2.5-
25.7; p<0.001). 
Table 4. Angiographic findings at the time of follow-up in Study I. 
Continuous variables are presented as the median and lower and upper quartiles (quartile 1; 
quartile 3) and categorical variables as numbers (n) and percentages (%), unless otherwise stated.
Angiographic findings I group (n=39) C group (n=43) p-value
Before index PCI
   Reference diameter (mm) 2.9 2.3;3.3 2.9 2.4;3.3 0.7
    Lesion length (mm) 27.8 21.7;36.3 30.1 20.1;40.0 0.6
   Minimal lumen diameter (mm) 1.1 0.7;1.4 1.0 0.8;1.2 0.8
   Percentage diameter stenosis 59.9 51.2;73.2 63.0 52.3;75.3 0.5
At index PCI
   Multiple stents in one lesion 6 6 1.0
   Balloon-to-artery ratio 1.1 1.0;1.3 1.1 1.0;1.1 0.2
After index PCI 
   Minimal lumen diameter (mm) 2.6 2.3;3.0 2.7 2.2;3.1 0.7
   Percentage diameter stenosis 12.0 5.8;22.4 13.4 6.6;22.1 0.9
At 6 months
   Minimal lumen diameter (mm) 1.8 1.2;2.4 1.6 1.2;2.1 0.4
   Percentage diameter stenosis 33.4 21.3;60.6 39.5 29.3;57.6 0.4
   Restenosis 16  41 19  44 0.8
   Target lesion revascularisation 6 15 5 12 0.7
   Late loss (mm) 0.78 0.31;1.27 0.77 0.49;1.33 0.8
PCI=Percutaneous Coronary Intervention
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In patients without a previous MI, the FBG at randomisation (median 7.5 (6.0;9.4) mmol/L) 
was somewhat higher compared with that in patients with a history of MI (FBG median 6.9 
(6.5;7.6) mmol/L; p=0.07) and a univariable predictor of restenosis (OR 1.5, 95% CI 1.1-2.1; 
p=0.02), while this was not the case in patients with a history of MI (OR 1.2, 95% CI 0.6-
2.2; p=0.6). Actual diabetes treatment at six months, irrespective of randomisation, did not 
influence the rate of restenosis (Figure 14).
Studies II and III
Detecting glucose perturbations in patients with ACS
The importance of time point and infarct size
The baseline characteristics of the 70 patients with a transmural MI and the 102 patients with 
a subendocardial MI in Study II are shown in Table 5, while glucose categorisation by means 
of OGTT is shown in Figure 15.
As outlined in Figure 15, a pre-discharge OGTT was performed in 67 (96%) of the patients 
with a transmural MI and it revealed that 31% were normal, while 33% had IGT and 36% 
T2DM. Three months later, these percentages were 35%, 39% and 26% in the 56 (80%) 
patients in whom the test was repeated, representing a reproducibility of 39% (κ=0.23, 
p=0.03). Among the 102 patients with a subendocardial MI, a pre-discharge OGTT was 
performed in 92 (90%) of them, classifying them as normal or with IGT or T2DM in 35%, 
35% and 30% respectively. Three months later, these figures were 35%, 40% and 25% among 
the 78 (76%) patients who had a repeated OGTT, corresponding to a reproducibility of 55% 
(κ=0.40, p<0.001). 
Figure 14. Univariable predictors of restenosis in Study I (n=82). 
HbA1c=Hemoglobin A1c; FBG=Fasting Blood Glucose; MI=Myocardial Infarction; PCI= Percutaneous 
Coronary Intervention
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Admission glucose and FBG during the first two days were significantly higher in patients 
with transmural MI than in those with subendocardial MI (Figure 16). Insulin resistance 
measured as HOMA-IR on day two, pre-discharge and after three months did not differ 
between the two groups.
The diagnostic accuracy of fasting plasma glucose and HbA1c
Of the 79 patients in Study III, 52 (66%) were classified as having IGT and 27 (34%) as 
T2DM, according to the OGTT. As shown in Table 6, the baseline characteristics did not 
differ in patients with IGT compared with T2DM, except for FPG and two-hour post-load 
glucose (2hPG). HbA1c did not differ significantly between patients with IGT 39 (37;42) 
mmol/mol compared with T2DM 41 (38;44) mmol/mol (p=0.07). Diabetic status according 
to OGTT, FPG and HbA1c is shown in Figure 17. Two patients had T2DM according to 
HbA1c of whom one had IFG and IGT and one T2DM according to FPG and the 2hPG. 
Among the 52 patients defined by OGTT as having IGT, 14 had a normal FPG and 38 IFG, 
while four of the 27 T2DM patients had normal FPG and 13 IFG. 
Table 5. Clinical characteristics of the patients by infarction type in Study II.
Continuous variables are presented as the median and lower and upper quartiles (quartile 1; 
quartile 3) and categorical variables as numbers (n) and percentages (%), unless otherwise stated.
Variable Transmural MI 
(n=70)
Subendocardial MI 
(n=102)
p-value
Age (years) 61 55-70 66 58-73 0.03
Gender (male) 53 76 65 64 0.13
Previous medical history
   Smoking 53 76 64 62 0.10
   Hypertension 18 26 35 34 0.25
   Hyperlipidemia 8 11 16 17 0.51
   Myocardial infarction 11 16 21 21 0.55
Biochemistry
   CK-MB > 10 during MI (n) 70 100 90 88 0.002
   CRP day 2 (mg/L) 15.8 7.4;33.1 8.4 3.4;18.2 0.006
   Blood glucose admission (mmol/L) 7.0 5.9;7.8 6.0 5.6;7.0 <0.001
      Fasting day 2 (mmol/L) 5.7 5.2;6.2 5.3 4.8;6.0 0.01
      Fasting day 3 (mmol/L) 5.4 4.9;6.1 5.0 4.7;5.5 0.004
      Fasting day 4 (mmol/L) 5.3 4.9;5.7 5.2 4.6;5.6 0.14
   HOMA-IR day 2 3.3 1.6;4.8 2.8 1.7;4.1 0.60
      Discharge 2.5 1.5;3.7 2.2 1.4;3.5 0.42
      3 months 2.2 1.7;4.3 2.4 1.6;3.6 0.67
Abnormal glucose regulation 
(IGT or T2DM)
   At discharge 46 69 60 65 0.73
   At 3 months 37 65 52 65 1.00
CK-MB=Creatine Kinase–MB; CRP=C-Reactive Protein; HOMA-IR=HOmeostasis Model Assessment of Insulin 
Resistance; IGT=Impaired Glucose Tolerance; MI=Myocardial Infarction; T2DM=Diabetes Mellitus type 2
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Figure 15. Patients divided according to glucose categories in Study II. 
ECG=ElecroCardioGram; IGT=Impaired Glucose Tolerance; MI=Myocardial Infarction; NGT=Normal 
Glucose Tolerance;  OGTT=Oral Glucose Tolerance Test; T2DM=Diabetes Mellitus type 2
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Figure 16. Glucose level divided by infarct size in Study II. 
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Table 6. Pertinent characteristics of patients in Study III divided according to glucose 
category defined by OGTT. Continuous variables are presented as the median and lower and 
upper quartiles (quartile 1; quartile 3) and categorical variables as numbers (n) and percentages 
(%), unless otherwise stated.
Variable IGT (n=52) T2DM (n=27) p-value
Age (years) 66.5 61.8;73.7 69.3 62.0;73.4 1.00
Gender (males) 45 87 19 70 0.13
Previous medical history
    Smoking 35 67 20 74 0.61
    Hypertension 29 56 14 52 0.81
    Hyperlipidemia 17 33 8 30 1.00
    Myocardial infarction 8 15 5 19 0.76
    PCI/CABG 11 21 7 26 0.78
Diagnosis at discharge
   STEMI 21 40 16 59 0.15
   NSTEMI 25 48 10 37 0.47
   Unstable angina pectoris 6 12 1 4 0.71
Treatment at discharge
    Aspirin 50 96 26 96 1.00
    Clopidogrel 51 98 27 100 1.00
    Beta blocker 49 94 25 93 1.00
    ACE or ARB inhibitor 47 90 21 78 0.17
    Statin 50 96 27 100 0.54
Demographic and biochemical 
variables at randomisation
    BMI (kg/m2) 27.7 25.0;29:0 26.9 24.0;28.6 0.37
    Cholesterol (mmol/L) 4.8 4.2;5.8 4.5 3.8;4.9 0.13
    LDL (mmol/L) 3.0 2.6;3.8 3.0 2.0;3.3 0.21
    HDL (mmol/L) 1.0 0.9;1.3 1.0 0.8;1.2 0.10
    Fasting plasma glucose (mmol/L) 6.0 5.5;6.4 6.3 5.7;7.2 0.03
    Plasma glucose 2h (mmol/L) 9.0 8.3;9.7 11.8 11.1;13.7 <0.001
    HbA1c (mmol/mol) 39 37;42 41 38;44 0.07
ACE=Angiotensin-Converting Enzyme-inhibitor; ARB=Angiotensin Receptor Blocker; BMI=Body Mass Index; 
CABG=Coronary Artery Bypass Grafting; HbA1C=Haemoglobin A1C; HDL=High Density Lipoprotein; IGT=Impaired 
Glucose Tolerance; LDL=Low Density Lipoprotein,; NSTEMI=Non ST-Elevation Myocardial Infarction; OGTT=Oral glucose 
Tolerance Test; PCI=Percutaneous Coronary Intervention; STEMI=ST-Elevation Myocardial Infarction; T2DM=Diabetes 
Mellitus type 2
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Table 7. Clinical characteristics of the patients in Study IV.
Patient 
no
Diagnosis at 
discharge
Age*
(years)
BMI*
(kg/m2)
BP*
(mm Hg)
Observation** 
(days)
Antithrombotic
therapy**
1
Heart 
failure
T2DM
71 29 95/55 3 Warfarin 
2 NSTEMIT2DM 80 25 125/70 3
Fondaparinux 
Aspirin 
Clopidogrel 
3 STEMI 64 36 160/80 3
Fondaparinux day 1
Aspirin 
Clopidogrel 
4 Heart failure 41 34 100/55 3
Aspirin 
Clopidogrel 
5 STEMI 55 30 110/55 3
Enoxaparin 
Aspirin 
Clopidogrel 
6
Heart 
failure
T2DM
73 40 120/70 2 Enoxaparin 
7 STEMI 46 32 95/60 3 Aspirin Clopidogrel 
8
Unstable 
angina 
pectoris
59 25 117/78 2
Fondaparinux day 1
Aspirin 
Clopidogrel 
9 STEMI 74 113/77 2
Abciximab day 1
Aspirin 
Clopidogrel 
10 STEMI 78 26 105/70 3
Fondaparinux 
Aspirin 
Clopidogrel 
11 NSTEMI 66 30 128/74 2 Aspirin Clopidogrel 
12
Unstable 
angina 
pectoris
T2DM
75 32 130/70 3
Enoxaparin day 2, 3
Warfarin 
Aspirin 
Clopidogrel 
13 NSTEMIT2DM 63 26 140/60 2
Fondaparinux 
Aspirin 
Clopidogrel 
14 STEMIT2DM 59 30 125/80 2
Abciximab 
Aspirin 
Clopidogrel 
*At study inclusion ; **During hospitalisation
BMI=Body Mass Index; BP=blood pressure; NSTEMI=Non ST-Elevation Myocardial Infarction; STEMI=ST-Elevation Myocardial Infarction; 
T2DM=Diabetes Mellitus type 2
Figure 17. Diagnosis of T2DM in Study 
III by different methods. 
FPG=Fasting Plasma Glucose
HbA1c= Hemoglobin A1c
2hPG=2 hour Post load Glucose OGTT
T2DM=diabetes mellitus type 2 
OGTT=Oral Glucose Tolerance Test
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Study IV
Continuous glucose monitoring in ACS
The 14 patients, all males, included in Study IV are presented in Table 7.
A total of 266 matched pairs of glucose measurements were collected. The lowest and highest 
measured plasma glucose were 4.5 mmol/L and 18.7 mmol/L while the corresponding values 
in microdialysis fluid were 2.8 mmol/L and 17.9 mmol/L respectively. Of the paired data 
points, 82% fell within ±20% of the reference glucose. The Clarke error grid of comparison 
is shown in Figure 18. All measurements fell within zone A or B, of which 81% were within 
zone A. In four of the 14 patients, the microdialysis measurements did not correspond to the 
measured plasma levels of glucose, as the values obtained by means of microdialysis were 
consistently too low. No relationship between the site of the catheter, body composition, 
blood pressure, diagnosis, or medical treatment and discrepant values could be detected.
Study V
Beta-cell function in ACS
The baseline characteristics of the 71 patients are presented in Table 8, while biochemical 
and clinical characteristics at randomisation and at the follow-up visit after 12 weeks on 
randomised treatment are presented in Table 9. HbA1c improved from 40 to 38 mmol/mol 
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Figure 18. Plasma glucose in Study IV analysed by the Clark Error Grid Analysis. Values in Zone A; 
clinically accurate, Zone B; benign, Zone C; over corrections, Zone D; failure to detect and Zone E; 
erroneous.
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in the sitagliptin group and remained unaltered in the placebo group (p=0.004). At the time 
of randomisation, 24 (71%) patients in the sitagliptin group had IGT and 10 (29%) had 
T2DM and the percentages of glucose abnormalities in the placebo group were 23 (62%) 
and 14 (38%) respectively. After 12 weeks, 26 (76%) patients in the sitagliptin group had 
normalised their glucose tolerance according to the OGTT, while the corresponding number 
for the placebo group was 15 (41%; Figure 19). 
Table 8. Baseline characteristics of the patients in Study V. Continuous variables are 
presented as the median and lower and upper quartiles (quartile 1; quartile 3) and categorical 
variables as numbers (n) and percentages (%), unless otherwise stated.
Variable Sitagliptin (n=34) Placebo (n=37)
   Age (years) 69 61;77 66 61;72
   Gender (male) 29 85 29 78
Previous medical history
  Family history
     Cardiovascular disease   14 44 16 43
     Diabetes mellitus type 2 8 26 7 19
  Smoking habits
      Present 7 21 6 16
      Previous 15 44 22 60
  Hypertension 20 59 18 49
  Hyperlipidemia 10 29 11 30
  Angina pectoris 5 15 3 8
  Myocardial infarction 6 18 7 19
Procedures during hospitalisation
  Coronary angiogram 33 97 36 97
  PCI 32 94 32 86
Diagnosis at discharge
  STEMI 16 47 16 43
  NSTEMI 14 41 18 49
  Unstable angina pectoris 4 12 3 8
Treatment at discharge
  Aspirin 33 98 36 97
  Clopidogrel 34 100 36 97
  Betablocker 31 91 35 95
  ACE or ARB inhibitor 30 88 32 86
  Statin 34 100 35 95
ACE=Angiotensin-Converting Enzyme-inhibitor; ARB=Angiotensin II receptor blocker ; NSTEMI=Non ST-Elevation 
Myocardial Infarction; PCI=Percutaneous Coronary Intervention; STEMI=ST-Elevation Myocardial Infarction
         Glucose-lowering and risk assessment in CHD
45
Beta-cell function expressed as IGI and AIRg did not differ between the sitagliptin group and 
the placebo group at baseline (69.9 vs. 66.4 pmol/mmol and 1394 vs. 1106 pmol · l-1 · min-1). 
After the 12-week study period, the IGI was 85.0 in the sitagliptin group and 58.1 pmol/mmol 
in the placebo group (p=0.019), while AIRg was 1909 and 1043 pmol · l-1 · min-1 (p<0.0001) 
respectively (Figure 20 a-b). Fasting and 120-minute post-load levels of proinsulin decreased 
in both groups at 12 weeks, the latter somewhat more in the sitagliptin group (Table 9). 
Insulin resistance, estimated as HOMA-IR, and FPG did not change significantly in either of 
the two groups during follow-up (Figure 20 c-d).
Table 9. Biochemical and clinical characteristics presented at randomisation and after 
12 weeks of treatment in Study V. Continuous data are presented as median (quartile 1; 
quartile 3) and categorical as numbers (%) unless otherwise stated. P-values represent 
comparison of delta values between groups at 12 weeks.
Parameter Baseline 12 weeks          p
Sitagliptin Placebo Sitagliptin Placebo
(n=34)                          (n=37) (n=34)                          (n=37)
Physical examination
  Blood pressure
     Systolic (mmHg) 120 116;145 125 113;133 125 120;140 130 120;140 0.257
     Diastolic   (mmHg) 73 70;80 75 70;80 75 70;80 75 70;85 0.259
  Heart rate (bpm) 59 51;64 56 52;61 55 49;61 52 48;58 0.935
  Weight (kg) 84 76;90 82 75;93 83 74;89 80 74;93 0.115
Biochemistry
  Troponin I max (ng/L) 11.0 0.5;27.6 5.5 0.6;19.0 - - - - -
  Plasma glucose at
  admission  (mmol/L) 
6.1 5.8;7.6 6.3 5.9;7.2 - - - - -
  Glucose fasting 
  (mmol/L)
6.1 5.5;6.6 6.0 5.8;6.7 5.8 5.5;6.0 5.9 5.7;6.5 0.429
  HbA1c 
  (IFCC mmol/mol)
40 37;42 40 37;43 38 36;42 40 37;43 0.004
  Insulin fasting 
  (pmol/L)
67.5 41.3;76.7 63.7 44.1;83.7 68.7 42.3;88.5 53.1 45.5;84.0 0.586
  Proinsulin fasting 
  (pmol/L)
12.9 9.1;19.5 12.9 9.6;16.1 10.2 7.3;15.6 11.0 7.7;19.3 0.101
   Proinsulin 120 min 
   OGTT (pmol/L)
109.2 69.9;177.2 115.6 76.0;156.2 64.6 43.9;90.1 76.9 60.1;111.0 0.094
 Blood lipids
     Total cholesterol
     (mmol/l)
4.6 4.2;5.6 4.6 4.0;5.9 3.6 3.2;4.4 3.9 3.5;4.3 0.699
     LDL (mmol/L) 3.0 2.3;3.7 3.0 2.3;3.9 2.1 1.7;2.5 2.2 1.9;2.6 0.948
     HDL (mmol/L) 1.0 0.9;1.2 1.0 0.8;1.2 1.0 0.9;1.2 1.1 0.9;1.3 0.222
     Triglycerides 
     (mmol/L)
1.1 0.8;1.9 1.3 1.1;1.8 1.1 0.8;1.3 1.2 0.9;1.5 0.856
HbA1C=Haemoglobin A1C;  HDL=High Density Lipoprotein; IFCC=International Federation of Clinical Chemistry 
standard; LDL=Low Density Lipoprotein; OGTT=Oral Glucose Tolerance test
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Figure 20 a-d. The primary endpoint beta-cell function in Study V expressed as the 
insulinogenic index (20a) and AIRg (20b). Fasting plasma glucose (20c) and HOMA-IR (20d).  
AIRg=Acute Insulin Response to glucose; FPG=Fasting Plasma Glucose; HOMA-IR= 
HOmeostatic Model Assessment Insulin Resistance; IGI=InsulinoGenic Index
Figure 19. Glucose tolerance category according to OGTT at randomisation in Study V and after 12 
weeks of treatment divided by treatment group. 
IGT=Impaired Glucose Tolerance; NGT=Normal Glucose Tolerance; OGTT=Oral Glucose Tolerance 
Test; T2DM=Diabetes Mellitus type 2
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GENERAL  DISCUSSION
Glucose control in patients with stable CAD
The fact that hyperglycaemia is related to increased CVD morbidity and mortality has 
been demonstrated in different clinical settings comprising general populations (186-188) 
and patients with stable CAD (103) or ACS (94, 101, 102, 189). The risk associated with 
increasing glucose levels is continuous and extends below the diagnostic threshold for T2DM 
(95, 190). 
For many years, T2DM treatment focused on glucose lowering, based on the possibility to 
reduce microvascular complications (191, 192), and it is only during the last few decades that 
it has been acknowledged that glucose control may have an impact on the CVD prognosis. 
The insight into the negative impact of hyperglycaemia opened the door to attempts to 
improve outcome by reducing untoward glycaemia. The tool for managing hyperglycaemia 
was originally mainly insulin, subsequently supplemented by other pharmacological agents 
such as insulin secretagogues, biguanides and, more recently, glitazones and GLP-1-related 
drugs. 
The impact of intensive insulin-based glucose control on the restenosis rate in patients 
with established T2DM was investigated in the IDA trial (Study I). There are in fact 
observational data indicating that strict glycaemic control may reduce the need for target 
vessel revascularisation (193, 194). Insulin was chosen as a suitable agent as, in addition to its 
glucose-lowering capacity, it has anti-atherogenic properties inducing endothelial-dependent 
vasodilation by increasing NO production via the PI3K pathway, which also mediates 
VSMC quiescence. Further, insulin infusion inhibits platelet aggregation and reduces plasma 
markers of inflammation (195). Conversely, it has also been argued that insulin may have 
pro-atherogenic effects by enhancing the proliferative response after a PCI, especially in 
the presence of insulin resistance, possibly by potentiating the expression of mitogenic 
factors, e.g. insulin-like growth factor-l (IGF-1), and increasing VSMC proliferation via the 
MAPK pathway (121, 196). Disappointingly the IDA trial did not support the hypothesis 
that insulin-based, tight glycaemic control would lower the restenosis rate. These findings 
were recently confirmed by the STREAM (STent Restenosis And Metabolism) trial in which 
addition of insulin did not influence in stent restenosis in patients with T2DM (197). Among 
potential explanations, it is important to consider that the IDA patients had a history of 
T2DM for six years and that they all had symptomatic CAD. At this fairly late stage of their 
disease, when the T2DM has progressed for several years, it may be too late to influence 
the development of CVD complications. Similar findings have been reported from three 
large trials, ADVANCE; Action in Diabetes and Vascular Disease: Preterax and Diamicron 
Modified Release Controlled Evaluation, ACCORD; the Action to Control Cardiovascular 
Risk in Diabetes and VADT; Veterans Affairs Diabetes Trial, exploring the concept of 
reducing CVD events by means of intensive glucose lowering (137-139). Even if substantial 
glucose lowering was achieved in the intensively treated groups, the event rates were higher 
than in the control groups in which glucose levels were less well controlled. The patient 
populations in these trials had established T2DM since eight to ten years. In contrast to this 
disappointing outcome, it seems as if treatment aimed at optimising glucose levels soon 
after the identification of patients with T2DM is more rewarding. In the UKPDS, intensive 
glucose-lowering treatment with sulphonylurea/insulin or metformin was compared with 
lifestyle advice in patients with newly detected T2DM. During the initial 10 years of follow-
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up, the groups differed in glucose control in favour of those given glucose-lowering drugs. 
Treatment with metformin resulted in a significant reduction in myocardial infarction and 
sulphonylurea/insulin therapy had a similar effect, however, only borderline significant. 
Continued follow-up of the UKPDS patients revealed a significant reduction in CVD 
morbidity and mortality after 17 years, although the difference in glucose control had 
diminished between the intensive and the routinely treated group (136). The beneficial 
effects of early institution of glucose-lowering treatment to prevent CVD are also supported 
by observational data from the Euro Heart Survey on Diabetes and the Heart (141) and the 
STOP-NIDDM trial (198). It therefore appears as if optimising glucose control in patients 
with advanced atherosclerosis and T2DM for several years is of little help. The potential 
benefits of glucose lowering may have been lost since the time window during which it 
may be possible to reverse the progress of CVD disease by tight glucose control has closed. 
This indicates that early detection and institution of effective glucose control may be of 
critical importance in improving the prognosis. 
An alternative explanation to the negative results in Study I may have been the lack of 
a difference in glucose levels between the two groups. This demonstrates how difficult it 
may be to achieve glucose control in patients with T2DM even in the setting of a controlled 
trial. Surprisingly, patients in the intensively treated group, who were referred to a specialist 
in diabetology, had the same level of glucose as those in the control group after six months 
of follow-up. Moreover, other trials, attempting to achieve glucose normalisation by means 
of insulin in patients with T2DM and established CVD disease, failed in this respect (124, 
199). In Study I, as well as in the DIGAMI 2 trial, it was hypothesised that insulin could 
have positive effects on the prognosis in patients with T2DM and established CAD, but 
this could not be confirmed. This indicates that insulin may not be the optimal drug in 
this category of patients, at least not when no difference in glucose control is achieved. 
A recent report from the DIGAMI 2 trial supports this notion, demonstrating that insulin, 
compared with sulphonylurea, metformin or no drugs, did not improve the prognosis in 
these patients; rather the contrary, as manifested by a higher proportion of non-fatal re-
infarctions and stroke in the insulin-treated group (200).
The implications of Study I may be difficult to interpret in the era of modern PCI 
technology, when the introduction of DES has reduced the restenosis rate in all patients, 
including those with T2DM. But long-term studies are scarce and epidemiological studies 
consistently report that patients with DM have a considerably poorer prognosis after a PCI 
(110). Accordingly, attempts to improve the outcome remain important. The impact of 
glucose control continues to be of interest, not the least since Study I revealed a significant 
relationship between the pre-procedural FBG and the subsequent restenosis rate. The 
importance of the pre-procedural glucose level is also evident in other studies (194, 201, 
202), indicating that targeting glucose normalisation during the time prior to, and maybe 
also, following a PCI may have a beneficial impact on the subsequent prognosis. However, 
the tools to achieve this need to be carefully considered when preparing these trials.
Glucose control in patients with ACS
Even if insulin appears to be less attractive for the long-term treatment of patients with 
T2DM and CAD (200), it remains the best option when treating patients admitted with ACS. 
Insulin has a rapid onset of action and can be titrated according to the prevailing situation. In 
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patients with ACS, the risk of mortality or non-fatal CVD events is amplified with increasing 
glucose levels. In this setting, it is reasonable to assume that lowering glucose will improve 
the prognosis. However, this concept may be challenged. As outlined in the introduction, 
the first DIGAMI study (122) demonstrated improved survival by means of insulin-based 
intensified glucose control in patients with DM and AMI, but subsequent trials attempting to 
confirm and extend these findings failed (124, 125). A meta-analysis comprising data from 
the three studies using a glucose-insulin infusion with the aim of achieving glucose control 
(DIGAMI 1, 2 and HI-5) showed that the treatment did not reduce mortality in the absence 
of glucose control (RR 1.07, 95% CI 0.85 to 1.36, p=0.547) (203). During the first 24 hours 
of hospitalisation, both HI-5 and DIGAMI 2 succeeded in reducing glucose levels, but, in the 
HI-5 study, there was no significant difference between the intervention and control groups 
and, in the DIGAMI 2 trial, the difference between the groups was small. These two studies 
must therefore be regarded as inconclusive, due to a lack of a significant improvement in the 
glucose levels of intensively treated patients, making the findings in DIGAMI 1 unopposed. 
Accordingly, it is still an open question whether the effective control of hyperglycaemia by 
means of insulin will improve the prognosis in T2DM patients with AMI.
One problem when it comes to treatment aiming at glucose normalisation during the acute 
phase of ACS is the fear of hypoglycaemia induction which has been related to an increased 
mortality risk in patients with ACS (204-206). These concerns were in fact discussed as 
a possible reason for the failure to reach the set glucose targets in DIGAMI 2 and HI-5. 
It has been claimed that hypoglycaemia, rather than being a cause in itself, is a marker of 
high risk due to other medical conditions (207, 208). Glucose variability, which may be a 
result of insulin treatment, is another factor that may explain the lack of consistent, positive 
results. In retrospective studies from surgical intensive care units, glycaemic variability is 
associated with an increased risk of mortality (209, 210). Similar findings have been reported 
in populations admitted for medical indications (211, 212), although glycaemic variability 
may be less important in patients with DM (213). 
These concerns, in combination with the failed attempts to achieve tight glucose control in 
DIGAMI 2 and HI-5, illustrate the need for new tools for glucose monitoring and guiding 
the administration of insulin. One solution would be to use a reliable, continuous glucose 
monitoring system (CGMS). A pilot study among nurses at a CCU found these devices 
helpful, but only after a training period with this new technology (214). In a subsequent 
randomised trial, 20 STEMI patients were assigned to either 48 hours of strict glycaemic 
control with a subcutaneous insulin pump augmented by continuous glucose monitoring or 
standard management with glucose measured by blinded continuous glucose monitoring. 
Hyperglycaemia was effectively reduced by the sensor-augmented insulin pump, but at the 
cost of a small yet significant increase in hypoglycaemic episodes (215). The studies quoted 
used a subcutaneous CGMS developed for home glucose monitoring of patients with DM 
(MiniMed CGMS and The Paradigm Real-Time system; Medtronic MiniMed, Northridge, 
California, USA). When monitoring patients with ACS, it is, however, important that the 
device picks up changes in the glucose quickly, alerting the staff for dosage adjustment. In 
this perspective, intravenous glucose measurement rather than recordings from subcutaneous 
interstitial fluid seem preferable, as it is independent of tissue perfusion. This was the 
reason for the choice of the microdialysis system in Study IV. Further, when relying on 
measurements to steer insulin intervention, accuracy is crucial, especially in the lower glucose 
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ranges where a difference of one or two millimoles may distinguish good glucose control 
from hypoglycaemia. During extended observations, the microdialysis catheter tended to 
display measurements as too low. The study design did not allow a full analysis of the 
reasons for the discrepancy between the glucose concentrations measured at the laboratory 
and the microdialysis technique. Possible explanations may be the coating of the catheter or 
impaired blood flow in the vessel. Thus adjustments have to be made before this system can 
be regarded as reliable. 
Detection of glucose abnormalities in patients with CAD
Since glucose abnormalities are common and prognostically important in patients with stable 
as well as unstable CAD, the actual gluco-metabolic state should be explored. In fact, the 
mere presence of CAD should lead to an investigation of glucose metabolism, according 
to European guidelines (36). Importantly, glucose perturbations are not always apparent 
unless they are actively screened for. When identifying risk subjects, the accuracy of the 
screening method is of importance, opening the door to the initiation of the correct preventive 
measures. When comparing different screening methods, it is important to take account of the 
fact that glucose measurements, due in part to sample collection and processing, have higher 
within-individual day-to-day variability than HbA1c, amounting to about 17% for the OGTT, 
6-15% for FPG and < 2% for HbA1c (216, 217). The FPG is less sensitive and identifies 
different populations to some extent compared with the OGTT (186, 218, 219). HbA1c is 
the most specific but least sensitive of the three methods for detecting glucose abnormalities 
(220). Despite this shortcoming and due to its convenience, it has been suggested that HbA1c 
identifies more people with glucose perturbations in a general population than FPG (221) 
and probably also OGTT. This method bypasses the problem of the day-to-day variability of 
glucose values and avoids the need for the individual to fast. 
In patients hospitalised due to ACS, the method for screening, as well as the optimal time 
point, are subject to debate. Studies II and III investigate diagnostic tools and what may 
influence the screening methods in a high-risk population of patients with a recent ACS. 
Glucose is often measured routinely at some point during hospitalisation for an ACS, at 
admission, fasting or at random. The diagnosis of glucose disturbances in patients with ACS 
does not differ from what is required in other groups, i.e. at least two pathological values 
are needed for the diagnosis of T2DM in the absence of symptoms of hyperglycaemia. Even 
if no formal diagnosis is made, elevated glucose levels per se should, however, warrant 
attention, as they indicate an increased risk. As demonstrated in Study III, the current HbA1c 
diagnostic cut-off of 48 mmol/mol only identified two patients, and the FPG only ten of the 
27 patients classified as having T2DM by an OGTT. Due to their lower sensitivity, the use of 
FPG and HbA1c alone will result in ineffective screening, as many individuals with glucose 
aberrations will remain undetected. Other limitations are that HbA1c may be affected by 
a variety of genetic and haematological factors such as anaemia and haemoglobinopathies 
(35, 222). Moreover, depending on the method of analysis, increased levels of triglycerides, 
bilirubin and white blood cells may interfere with the result (217). HbA1c is a simple test to 
perform and, if elevated, it indicates an increased risk, but a normal HbA1c should prompt 
further investigations and preferably an OGTT.
The OGTT has been criticised for being inconvenient and for its poor reproducibility, as 
the results are influenced by previous dietary intake, factors affecting insulin sensitivity and 
         Glucose-lowering and risk assessment in CHD
51
secretion, such as smoking and physical activity, as well as gastrointestinal hormones. As 
further outlined below, the influence of hyperglycaemia induced by stress is an additional 
confounder, not the least important during an ACS. The within-individual variability of an 
OGTT may result in a patient being classified as having T2DM on one occasion and IGT the 
next, especially in patients close to the cut-off levels (223). 
However, as clearly demonstrated in Study III, the OGTT adds information compared with 
FPG or HbA1c and the majority of patients with glucose perturbations were indeed disclosed 
by an increased 2hPG. Information on postprandial glucose elevations, which increase prior 
to the FPG during the progression of glucose perturbations towards overt T2DM (see Figure 
3), can only be derived from an OGTT. This is of special importance in risk prediction, as 
the 2hPG in this respect is superior to FPG (186). Moreover, patients in the range of IGT run 
an increased risk of CVD morbidity and mortality compared with those with isolated IFG 
(187, 224). 
One limitation of Study III (and II) is the lack of repeated OGTTs, especially so if the purpose 
was to diagnose T2DM. However, in ACS patients, the primary aim is not to establish the 
diagnosis of T2DM but rather to assess glucose perturbations as a continuously increasing 
risk factor of importance to take into account when assessing a patient’s total CVD risk. 
The sensitivity of the test that is chosen is especially important when dealing with high risk 
individuals, a strong reason to use an OGTT in such patients with normal HbA1c and FPG. 
One important question is whether stress impairs the reliability of screening for glucose 
abnormalities in patients hospitalised with ACS. Hyperglycaemia, detected by glucose 
measurements during hospitalisation, may be related to a catecholamine-induced stress 
reaction, but it may also indicate an underlying glucose abnormality in need of further 
investigation. In this context, the HbA1c has an advantage as it reflects the mean glucose 
levels during the past four to eight weeks (225) uninfluenced by short-term glycaemic 
variations. However, it misses a substantial number of patients with IGT or T2DM, as already 
discussed.
The impact of timing on the results of an OGTT was explored in Study II and the topic has 
also been investigated in other studies where serial OGTTs have been performed during 
and after hospitalisation for an ACS (226-231). In these studies, the number of glucose 
abnormalities during hospitalisation varied between 46-79%, with a tendency to improve at 
follow-up, to a percentage of 25-42%, especially if the initial OGTT was performed close to 
admission, i.e. within 48 hours (228-230) and in younger patients with a first-time MI (228, 
231). In Study II, two thirds of the patients still had an abnormal glucose regulation when 
the OGTT was repeated after three months, even if some patients close to the cut-off levels 
may have transferred up or down to another glucose category, thereby impairing the value of 
agreement. Compared with the studies by Knudsen and Bronisz, the patients in Study II were 
five to six years older, which may have contributed to more permanent beta-cell dysfunction, 
as this has a tendency to decline with age. Study II further suggests that a large infarct 
may aggravate stress, thereby influencing the glucose levels during the very first days after 
admission. This impact declines during the hospitalisation, making the results of an OGTT 
performed four to seven days after admission reliable. This notion is confirmed by other 
studies in which the impact of infarct size, determined as CKmax (227) or troponin T levels 
(230), did not relate to the OGTT result. Bronisz et al. performed an OGTT immediately prior 
to discharge and at three months in STEMI patients. They reported an improvement in glucose 
tolerance but did not reveal any relationship with the extent of myocardial necrosis (231). 
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When the GAMI study (Study II) was performed, more than ten years ago, a hospitalisation 
period of five days was not unusual, while many patients nowadays are discharged after 
just three days, which means that the OGTT needs be performed closer to the acute event if 
conducted during hospitalisation. To increase the accuracy of an OGTT in ACS patients the 
procedure is better scheduled at the first follow-up visit when the potential effects on glucose 
metabolism of acute stress have declined.
During the last decade, awareness of glucose disturbances in ACS patients has increased 
and clinical practice has changed. Rehabilitation programmes after an ACS focusing on 
improvements in lifestyle, including physical activity and food choices, have developed. It 
is to be hoped that this growing knowledge will contribute to a healthier lifestyle, resulting 
in recovered glucose tolerance after an ACS event. This may also be an explanation of the 
“spontaneous” improvement in glucose tolerance observed in Study III compared with Study 
II and perhaps also in some of the previously mentioned studies of OGTT in ACS. In fact, 
lifestyle interventions introduced during the early stages of glucose intolerance can delay 
further progress into T2DM and thereby potentially avoid CVD events (232, 233). There 
are however patients who do not recuperate in terms of glucose tolerance, despite lifestyle 
interventions. The early identification of patients with glucose abnormalities is important 
in order to optimise future treatment, which may include the initiation of glucose-lowering 
agents (141, 232, 234).
New options in glucose lowering - targeting beta-cell function
Although observational data indicate that an early pharmacological approach could improve 
the prognosis in patients with ACS and newly detected glucose perturbations, this has not 
yet been verified in randomised controlled trials (141). In general, glycaemic treatment has 
often focused more heavily on glucose lowering rather than targeting the pathogenesis of 
the perturbation, which may be a reason why even the use of insulin may eventually end 
in treatment failure, not the least in patients with reduced insulin sensitivity as a primary 
defect (235). Further, there are indications that the choice of glucose-lowering agent may 
have prognostic implications. As mentioned previously, a report from the DIGAMI 2 trial, 
as well as epidemiological data in patients with T2DM and AMI, imply potentially harmful 
effects of insulin or insulin secretagogues with an increased risk of CVD events and mortality 
compared with metformin, which appears to have a more desirable profile (200, 236-238). 
Thus metformin, which acts by increasing insulin sensitivity, is a logical choice as reflected 
by recent treatment recommendations (239). Other alternatives are the glitazones, which are 
strong insulin sensitisers with additional positive effects on beta-cell function (68), but their 
CVD safety is under debate, especially rosiglitazone (240, 241), which have been withdrawn 
from the European market.
As previous investigations by our group revealed high proinsulin levels reflecting beta-cell 
dysfunction in patients with ACS (104, 105), pharmacological agents targeting beta-cell 
function may be of special interest for further exploration in this setting. In the UKPDS, 
neither metformin nor sulphonylurea were able to prevent a 4% annual decline in beta-cell 
function (65), while rosiglitazone did somewhat better in the ADOPT study, with a 2% 
decrease compared with 6.1% in the glyburide group (p=<0.001) and 3.1% in the metformin 
group (p = 0.02) (242). 
         Glucose-lowering and risk assessment in CHD
53
The GLP-1 analogues and DPP-IV inhibitors are attractive compounds in this respect. GLP-1 
has been anticipated to have disease-modifying properties on beta cells via proliferative and 
anti-apoptotic actions primarily shown in T2DM rodent models, human cell lines and islets. 
Moreover, in reports from animal models, the DPP-IV inhibitor sitagliptin, used in Study V, 
has been demonstrated to restore islet morphology (243, 244) and reduce apoptosis in beta 
cells (245, 246). Exactly how these experimental findings translate into a clinical situation is 
still to be explored in more detail. In human studies, where the pancreatic beta-cell function 
is primarily estimated from glucose and insulin measurements, sitagliptin appears to improve 
beta-cell function in patients with established T2DM (247-254). Similar effects have also 
been reported for other DPP-IV inhibitors, suggesting a class effect rather than a specific 
effect for sitagliptin (255).
In Study V, the beta-cell function was improved by the DPP-IV inhibitor sitagliptin.
The clinical studies presented so far mainly recruited patients with T2DM, who had 
presumably lost a substantial amount of their beta-cell function. In these patients, there are 
still data indicating sustained effects of exenatide and sitagliptin after up to two to three 
years of treatment, especially if combined with metformin (256-258). Improvements in beta-
cell function have also been demonstrated in patients with IFG using the DPP-IV inhibitor 
vildagliptin (259). Initiating treatment at an early stage offers an opportunity to have beta-
cell function left to save. In Study V, all the patients had previously unknown glucose 
disturbances with modestly elevated glucose levels, which suggests that they are detected 
early in their diabetes career. The findings of increased proinsulin levels, as demonstrated in 
the GAMI study (104), were replicated in the present patient population in which these levels 
were in fact somewhat higher than in the GAMI study with a HOMA-IR index of the same 
magnitude, confirming the impaired beta-cell function in this group of patients. In the control 
group, as well as in the treatment group, the patients were given structured and reinforced 
lifestyle advice on food and physical activity, according to guidelines. This is a potential 
explanation for an average weight loss of two kg and the fact that 41% of the control patients 
had a normal glucose metabolism after three months. In contrast to the sitagliptin-treated 
group of patients, they did not improve their beta-cell function. The beneficial effects of a 
DPP-IV inhibitor on beta-cell function in the sitagliptin group should therefore be seen as 
a result achieved in addition to lifestyle-initiated improvements which, if permanent, may 
potentially delay the further development of hyperglycaemia and T2DM and hopefully also 
further CVD events.
Although DPP-IV inhibitors in general and sitagliptin in particular are well tolerated (260, 
261), the safety profile has not been extensively studied in patients with CAD, especially not 
with a recent ACS, and there are reports of potential drug interactions between sitagliptin 
and CVD agents (262-266). One important aspect of Study V was therefore to evaluate the 
feasibility of the early prescription of sitagliptin to patients with ACS. While small in patient 
numbers, Study V demonstrates that the drug was well tolerated, a finding that requires 
confirmation in larger sets of patient material. Furthermore, there are indications that DPP-
IV inhibitors such as sitagliptin have beneficial CVD effects apart from improvements in 
glucose control (169). In patients with T2DM, sitagliptin increased circulating endothelial 
progenitor cells, which may have potential favourable CVD implications (267). Moreover, 
the lipid profile is positively influenced by DPP-IV inhibitors (268, 269) and there are data in 
patients with CAD indicating that sitagliptin plays a cardioprotective role, showing enhanced 
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left ventricular response to stress, attenuated post-ischaemic stunning and improved global 
and regional left ventricular performance (270). When evaluating the impact of DPP-IV 
inhibitors on CVD events there seem to be a possible protective effect as indicated by a 
meta-analysis including 20,312 patients on DPP-IV inhibitors and 13,569 on comparator 
drug (271).
Future perspectives
Efforts to improve prognosis in dysglycaemic patients with CAD or at high risk for such 
conditions by a stringent glucose control has not been convincing, neither in the outpatient 
setting nor during hospitalisation. A possible explanation is inefficacy of available glucose 
lowering drugs, which although initially effective may provide insufficient glycemic control 
in the long term perspective, leaving insulin as the remaining option. However, even when 
given insulin, many patients do not reach recommended glucose targets and in addition, 
the treatment increases the risk for glucose swings, including hypo- and hyperglycemia. 
Lowering of glucose levels during the hospitalisation for an ACS may necessitate insulin 
administration. Such treatment may, however, be complicated to balance due to varying 
degree of stress, the possible impact of concomitant medications, variable food intake and 
a fear to induce hypoglycaemia. Development of new techniques as such as CGMSs may 
facilitate insulin based therapy by frequent, automatically delivered glucose values offering 
a potential to eliminate excessive blood sampling and to make the staff in coronary and 
intensive care units more confident in using adequate amounts of insulin and to enable 
titration towards tighter glucose targets. Reliable technology of that kind would open for the 
possibility to test the hypothesis of an improved prognosis by a stable tight glucose control 
guided by CGMS.
Many patients have their dysglycaemic condition discovered at admission for an acute 
coronary event. The high proportion of previously unknown glucose perturbations in patients 
with both stable and unstable CAD necessitates effective screening procedures within cardiac 
care. The HbA1c has recently been proposed as a diagnostic tool and may be useful as a 
complement but, an OGTT is considerably more sensitive for the detection or exclusion of 
glucose disturbances in such patients, as shown in this thesis. Thus an OGTT is advocated 
when FPG and HbA1c are normal to avoid that a large-scale proportion of patients with 
glucose perturbations remain undetected. In addition, an accurate identification of prediabetic 
states is important since the development of T2DM in patients with IGT may be prevented 
or retarded by means of lifestyle adjustments or, if needed pharmacological agents such as 
metformin or acarbose (232, 234). Since the cardiovascular prognosis can be improved in 
patients with glucose perturbations by an aggressive multifactorial approach, combining 
lifestyle advice with pharmacological treatment aiming at optimal blood pressure and lipid 
control, early detection is of importance (272, 273).
In the future, new treatment options should focus on the underlying pathophysiological 
mechanisms in patients with CAD and glucose perturbations. In ACS patients, in whom beta-
cell dysfunction seems to be an important characteristic, this may be of particular value as 
indicated by the present findings. Such compounds could hopefully delay T2DM progression 
and retard the atherosclerotic process by improving insulin secretion and possibly also 
other mechanisms, especially if initiated soon after the detection of the abnormal glucose 
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metabolism. In this context pharmacological agents such as GLP-1 analogues or DPP-IV 
inhibitors seem promising. Along with these there are other alternatives under development 
e.g. balanced peroxisome proliferator-activated receptor (PPAR) alpha and gamma agonists 
both targeting insulin sensitivity and lipid profile. The BEGAMI study (Study V) was designed 
as a pilot study for subsequent larger outcome studies investigating DPP-IV inhibitors as a 
new treatment option in patients with disturbed glucose metabolism and CAD. Pilot trials 
offer opportunities to study the drug in a smaller population, providing an initial indication 
if the drug has potentially beneficial effects and an indication whether the drug is safe to 
study in large cohorts of patients. In addition, the smaller pilot trial usually offers better 
opportunities for detailed exploration of pathophysiological mechanisms than in multicenter, 
large-scale trials. The explorative studies have by necessity to be followed by outcome trials 
focusing on cardiovascular mortality and morbidity to be accepted in patient management. 
It is hoped that presently ongoing endpoint-driven trials in the area (274, 275) will provide 
such evidence.
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CONCLUSIONS
1. Intensified insulin treatment does not reduce the rate of restenosis after a PCI in patients 
with T2DM. The glucose level prior to the procedure is a predictor of restenosis. To tar-
get glucose normalisation during the nearest time period prior to a PCI deserves further 
exploration.
2. The oral glucose tolerance test is a valid screening tool detecting more patients with glu-
cose abnormalities than fasting plasma glucose and HbA1c in patients with ACS. 
3. Continuous glucose monitoring by microdialysis technique appears promising in patients 
in a coronary care unit but further development of the technology is needed to improve 
the accuracy.
4. The DPP-IV inhibitor sitagliptin improves beta-cell function in patients with ACS and 
newly discovered glucose perturbations. The drug may safely be prescribed soon after an 
acute coronary event. 
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